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Gladiolin is a macrolide antibiotic with potent activity against Mycobacterium 
tuberculosis. It is biosynthesised by a trans-AT polyketide synthase (PKS) with 
many unique features including an O-methylation module, with a dedicated O-
methyltransferase (OMT) domain. In this work, the OMT-ACP didomains from 
the gladiolin PKS, as well as three others from trans-AT PKSs, were 
overproduced and purified. Their activity and substrate tolerance were 
determined, providing the first biochemical proof of O-methylation on 
polyketide assembly lines and revealing useful substrate promiscuity. The 
OMT domains were shown to fall into two clades, which appear to correspond 
their ability to interact with specific ACP domains. 
 
The gene cluster also contained two putative auxiliary genes of unknown 
function; gbnC that encodes for an asparagine synthetase, and gbnM which 
encodes for an amidase. Inactivation of gbnM generated a mutant producing 
a novel amide derivative of gladiolin, which maintained antimicrobial activity. 
Purified GbnM was shown to catalyse hydrolysis of the amide derivative to 
produce gladiolin. Although it was established, by in vivo gene deletion, that 
gbnC, proposed to be responsible for the initial amidation, plays an essential 




Figure 1: Gladiolin structure and biosynthetic gene cluster, highlighting the 
OMT domain containing region, and the genes gbnM and gbnC. 
   








1.1.1 The discovery of antibiotics 
 
The first discovered antibiotic, penicillin (1), has now been in clinical use for 
over 70 years. It was discovered serendipitously by the microbiologist 
Alexander Fleming in 1928, when he observed a zone around a contaminating 
fungus, Penicillium notatum, on an agar plate in which bacteria did not grow, 
and decided to investigate further2,3 (Figure 1.1). It took over a decade, and 
contributions from scientists worldwide to establish a method to mass-produce 
penicillin for clinical use, but since then penicillin and other antibiotics have 




Figure 1.1: The discovery and structure of the first antibiotic, penicillin. The 




The discovery of penicillin opened the eyes of the scientific community to the 
potential of biologically active secondary metabolites, and between the 1940’s 
and 1960’s nearly all of the natural product antibiotic classes used today were 
identified (Figure 1.2)4. The success of the golden era of antibiotic discovery 
can be in part accredited to Selman Waksman, who pioneered the systematic 
screening of soil-derived Actinomyces. The Waksman platform was simple 
and based on the principals of penicillin discovery; the soil-derived 
Actinomyces were screened for antimicrobial activity against test 
microorganisms by detecting zones of growth inhibition on an overlay plate5. 
The capability of the platform was realised in 1943 with the discovery of the 
first treatment for Mycobacterium tuberculosis, streptomycin (2), which was 
isolated from Streptomyces griseus6. After twenty years this platform became 
significantly less utilised, however, owing to the increasing difficulty of 
identifying novel compounds against the background of known compounds, 
as well as the emergence of antibiotic resistance. The appearance of antibiotic 
resistance diverted efforts towards chemically modifying the existing antibiotic 
scaffolds to overcome this problem, and away from the discovery of new 
antibiotics.  
 
1.1.2 Antibiotic modes of action 
 
For discovered antibiotics to be clinically applicable they must be chemically 
stable, readily soluble, be able to easily enter bacterial cells and inhibit critical 
pathways in pathogens that are absent or significantly different in mammalian 
cells. Antibiotics can be either bactericidal and kill bacteria (penicillin (1) and 
rifampicin (5)), or bacteriostatic and prevent the growth of bacteria 







Figure 1.2: The structure of a range of natural product antibiotics from the 







There are three main antibiotic targets; cell wall synthesis, DNA and RNA 
synthesis and protein synthesis (Figure 1.3). Penicillin (1) and vancomycin (8) 
are examples of antibiotics that act by inhibiting bacterial cell wall biosynthesis. 
The cell wall is made up of peptidoglycan, which is a covalently cross-linked 
polymer matrix made up of sugars and amino acids. Penicillin (1) works by 
preventing cross-linking of peptidoglycan whereas vancomycin (8) acts as a 
steric inhibitor of peptidoglycan maturation7,8. Although these two antibiotics 
target different steps in cell wall biosynthesis, they both ultimately lead to the 
loss of structural integrity of the bacterial cell, resulting in cell death by lysis. 
Rifampicin (5) on the other hand induces bacterial cell death by binding to RNA 
polymerase, and sterically preventing RNA elongation when the transcript 
becomes 2 to 3 nucleotides in length9. Generally, antibiotics that inhibit protein 
synthesis by binding to the ribosome are bacteriostatic rather than bactericidal. 
The ribosome consists of two subunits (30S and 50S subunits) both of which 
are targets for antibiotics. Chlortetracycline (6) is an example of an antibiotic 
that acts on the 30S subunit and prevents attachment of aminoacyl-tRNAs to 
the ribosome that are carrying the amino acid building blocks required for 




Figure 1.3: Antibiotic targets. Examples of antibiotics that act upon each of 




1.1.3 Antibiotic resistance 
 
Antibiotic resistance was quickly observed in pathogenic bacteria, with 
resistance having been identified for all clinically used antibiotics5. Bacteria 
are able to acquire resistance via mutations in their chromosomal genes and 
by horizontal gene transfer11. Antibiotic resistance genes (ARGs) pre-existed 
the clinical use of antibiotics owing to the fact that bacteria have encounter 
such compounds, which are produced by other microorganisms, in nature for 
millions of years, and evidence is emerging that some of the ARGs found in 
pathogenic bacteria actually originate from the producing microorganisms, 
which possess such genes to prevent suicide during the production of 
antibiotics12.  
 
There are three major resistance mechanisms employed by bacteria. The first, 
and one of the of the most successful mechanisms involves the use of 
enzymes to destroy or modify the antibiotic so that efficacy is lost13. Another 
mechanism involves the modification of the antibiotic target, this can be 
through genetic mutations or post-translational enzymatic modification of the 
target site. Vancomycin (8), an antibiotic that acts by inhibiting cell wall 
biosynthesis, is an interesting example where the antibiotic target is 
completely remodelled to avoid antibiotic binding. When resistant bacteria 
detect the presence of vancomycin they begin to change the cell wall 
composition so that efficacy is lost14. The third mechanism involves preventing 
the antibiotic from accessing the target. This is achieved by either reducing 
the permeability of the outer membrane to the antibiotic or by overexpressing 
efflux pumps to remove the antibiotic from the cell13. Often resistance to the 
same antibiotic is achieved through more than one these mechanisms. 
 
Antibiotic resistance is now becoming a worldwide problem, due to the 
increasing prevalence of multi-drug resistant bacteria, which are difficult or in 
some cases impossible to treat. The need to develop new therapies to 
overcome this problem has put antibiotic discovery back in the limelight. The 
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recent advent in genomics revealed that most bacterial species in fact remain 
uncultured, it is estimated that uncultured species outnumber cultured species 
by two or three orders of magnitude15. This highlights the huge, still untapped, 
potential of microorganisms in the search for new drugs, especially owing to 
the fact that developments in metagenomics enables bypassing the 
requirement of cultivation16. Much research is also being carried out to try and 
obtain a greater understanding of the complex biosynthetic machineries that 
are responsible for microbial natural products, in order to try and realise the 
potential of these systems for manipulation to create libraries of novel 
compounds with new activities.   
 
 
1.2 Polyketide synthases 
 
Polyketide synthases (PKSs) play an important role in microbial secondary 
metabolism and constitute one of the major mechanisms of antibiotics 
biosynthesis. Erythromycin (4), rifampicin (5) and chlortetracycline (6) are all 
polyketide antibiotics and despite their structural diversity they are all 
assembled from small acyl units by PKSs17–19. PKSs are evolutionarily related 
to fatty acid synthases (FASs), which play a fundamental role in primary 
metabolism and can be found across all organisms20,21. Many parallels can be 
drawn between these two biosynthetic machineries, thus logically PKSs were 
classified in the same way as FASs, according to the architecture and activity 
of their biosynthetic enzymes. 
 
Briefly, PKSs can be divided into three major classes. Type I PKSs are large, 
multifunctional enzymes that are arranged into modules, and within each 
module there are a number of active sites that are referred to as domains. The 
covalently bound biosynthetic intermediates are passed, in an orderly manner, 
from one domain to the next to build the polyketide22. Type II PKSs typically 
produce aromatic compounds (for example chlortetracycline (6)) and consist 
of a set of discrete mono- or bi-functional enzymes that are used iteratively to 
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assemble the polyketide chain, that is tethered to the PKS throughout the 
biosynthesis23. Type III PKSs iteratively utilise a single active site for all stages 
of the biosynthesis, differing fundamentally from the other two classes as the 
polyketide chain is built on coenzyme A (CoA), and is thus not always 
covalently attached to the PKS24. 
 
Increasing numbers of PKSs are being discovered, however, that don’t fit the 
type I, II and III paradigm but fit somewhere in-between these PKS classes25. 
To help account for this, type I PKSs can be further classified as either 
iterative, where a single module is used repeatedly to build the polyketide, or 
modular26. Modular type I PKS can be further classified still as either cis-AT 
PKSs or trans-AT PKSs, and will be discussed in greater detail in the following 
sections.  
 
1.2.1 Cis-AT PKSs 
 
The PKS responsible for the biosynthesis of 6-deoxyerythronolide B (6-dEB, 
9), the precursor to the clinically used antibiotic erythromycin (4), is an 
archetypal example of a cis-AT PKS and is one of the most-well studied PKSs 
(Figure 1.4). It consists of three PKS proteins and seven modules; the first 
module is responsible for the loading of the starter unit propionyl-CoA and the 
remaining 6 modules catalyse chain elongation, each incorporating a 
methylmalonyl-CoA extender unit, and modification of the growing polyketide 
chain17.  
 
1.2.1.1 The minimal catalytic module 
 
Each module responsible for catalysing chain elongation minimally consists of 
three domains: an acyl carrier protein (ACP) domain, an AT domain and a 
ketosynthase (KS) domain. The central component of each module is the ACP 
domain; a small, non-catalytic protein consisting of a 4-helical bundle27. 
Despite its simple structure, the ACP domain mediates interactions with all 
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domains within the module, the KS domain of the downstream module and 4’-
phosphopantetheinyl transferase, which converts the inactive apo-ACP 
domain to the active holo-form. 4’-phosphopantetheinyl transferase catalyses 
the addition of the 4’-phosphopantetheine moiety of CoA onto a conserved 
serine residue of the ACP domain, as shown in Figure 1.528. This creates a 
phosphopantetheinyl arm onto which intermediates in the biosynthesis are 




Figure 1.4: The biosynthesis of 6-dEB. The polyketide intermediates after the 
incorporation of each extender unit and the modifications of the growing 







Figure 1.5: Mechanism of the conversion of apo-ACP domains to holo-ACP 
domains catalysed by 4’-phosphopantetheinyl transferase, the catalytic 
glutamic acid residue is indicated. 
 
The role of the AT domain is to select for the appropriate extender (or starter) 
unit. Nearly all AT domains show high specificity for their cognate unit, with 
malonyl-CoA and (2S)-methylmalonyl-CoA being the most commonly utilised 
substrates, although many other substrates have been shown to be selected 
for by AT domains from PKSs (Figure 1.6)29,30. The loading of the extender (or 
starter) unit onto the ACP domain proceeds via the formation of an acyl-AT 
domain intermediate, which is formed by attack of the corresponding acyl-CoA 
by a conserved serine residue in the active site of the AT domain (Figure 
1.7)31. The acyl-AT domain intermediate is then subject to attack from the thiol 






Figure 1.6: Examples of starter and extender units utilised in polyketide 
biosynthesis by cis-AT PKSs. ACP domains are represented by black circles, 
and where this is the case, it is proposed that the AT domain offloads the 




Figure 1.7: Mechanism of the loading of the extender unit (methylmalonyl-
CoA for the 6-dEB PKS) or starter unit (propionyl-CoA for the 6-dEB PKS) onto 
the PKS catalysed by the AT domain, the catalytic histidine residue is 
indicated. R = starter or extender unit. 
 
The KS domain has two roles, it firstly interacts with the upstream ACP domain 
and catalyses the intermodular translocation of the polyketide intermediate 
onto its active site cysteine residue. Once the AT domain has loaded the 
extender unit onto the downstream ACP domain, the KS domain then 
catalyses the decarboxylative Claisen-like condensation of the extender unit 
with the growing polyketide chain, resulting in the formation of a new C-C bond 
(Figure 1.8). It has been shown, by site-directed mutagenesis of the active site 
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of the KS domain from module 1 of the 6-dEB PKS, that two conserved 
histidine residues play an essential role in catalysing these two reactions32. 





Figure 1.8: Mechanism of intermodular polyketide translocation and chain 
elongation catalysed by the KS domain. The catalytic histidine residues are 
indicated (with hydrogen bonds shown in grey) and the new C-C bond formed 
is shown in bold. R1 = polyketide chain and R2 = a-substituent derived from 
the extender unit. 
 
1.2.1.2 Accessory domains 
 
In addition to the key catalytic domains, each module may also possess a 
number of accessory domains that are responsible for introducing structural 
diversity to the polyketide. Ketoreductase (KR) domains act first, and catalyse 
the b-nicotinamide adenine dinucleotide 2’-phosphate (NADPH)-dependant 
reduction of the b-keto group, generated by the chain elongation reaction, to 
a hydroxyl group (Figure 1.9). This reaction proceeds in a stereospecific 
manner, with KR domains referred to as ‘A-type’ if they produce a (S)-
configured hydroxyl group and ‘B-type’ if they produce a (R)-configured 
hydroxyl group, this can be predicted from the amino acid sequence of the 
domain33,34. Interestingly, structural studies of A- and B-type KR domains 
revealed that the relative positions of the catalytic domains and NADPH are 
maintained in both of the structures, so it is proposed that stereoselectivity is 
imposed by the polyketide substrate entering the active site from different 
sides of the catalytic domain35. It has also been demonstrated that some KR 





Figure 1.9: Mechanism of the reduction of the b-keto group catalysed by the 
KR domain. The catalytic tyrosine residue is indicated. R1 = polyketide chain 
and R2 = a-substituent derived from the extender unit. The reaction is 
stereospecific, with stereochemistry determined by the orientation of the 
substrate in the active site. 
 
A dehydratase (DH) domain may then follow the KR domain, which generates 
an a / b-double bond through the syn- elimination of water (Figure 1.10)37. The 
elimination reaction is sensitive to the stereochemical configuration of the b-
hydroxyl group, thus DH domains most commonly precede B-type KR 










Figure 1.10: Mechanism of the reduction of the b-hydroxyl group catalysed 
by the DH domain. The catalytic histidine and aspartic acid residues are 
indicated. R1 = polyketide chain and R2 = a-substituent derived from the 
extender unit. 
 
The double bond generated by the DH domain may then be further reduced 
by an enoylreductase (ER) domain to give a saturated moiety (Figure 1.11). A 
crystal structure of the KR-ER didomain from the spinosyn PKS revealed that 
the NADPH cofactor is positioned to first add a proton to the b-carbon. A 
second proton is then abstracted from either a tyrosine residue (giving an (S)-
configured stereocentre at the a-position) or a lysine residue (which transfers 
a proton if the tyrosine moiety is absent, to give a (R)-stereocentre at the a-




Figure 1.11: Mechanism of the reduction of the a / b-double bond catalysed 
by the ER domain. The catalytic tyrosine and lysine residues are indicated. 




1.2.1.3 The principal of co-linearity 
 
The 6-dEB PKS demonstrates perfectly the principal of co-linearity, whereby 
the PKS domain architecture corresponds directly to the polyketide structure.  
The modules operate in the order they are positioned and each module is used 
only once. Co-linearity, which is observed for the majority of cis-AT PKSs, 
means that in general the structure of natural products from these systems 
can be predicted, with a good degree of confidence, from the sequence of the 
domains. This principal has been exploited for the bioengineering of numerous 
cis-AT PKS assembly lines38. Targeted genetic manipulations, such as 
inactivation and substitution of the catalytic domains, have been used to create 
polyketide derivatives with structural modifications correlating directly to the 
introduced mutations, which in turn have provided extensive experimental 
evidence for this principal.  
 
Naturally there are exceptions to the rule, and with the number of known PKS 
assembly lines rapidly expanding, increasing numbers of non-canonical cis-
AT PKSs are being reported29. Notable deviations from co-linearity in these 
systems include ‘module stuttering’ and ‘module skipping’. ‘Module stuttering’ 
that was essential for biosynthesis was first reported for the aureothin PKS, 
where module 1 of the PKS was shown to act in an iterative fashion, and 
catalyse two rounds of chain elongation40. This phenomenon has since been 
identified in numerous other systems. An interesting example of ‘module 
skipping’ can be found in the biosynthesis of quartromicin, which is composed 
of two polyketide chain intermediates, one shorter than the other. Both of these 
biosynthetic intermediates are built on the same PKS assembly line, which 
performs programmed module skipping half of the time to generate the shorter 







1.2.1.4 Post-PKS modifications 
 
Once the end of a polyketide assembly line has been reached the resultant 
polyketide is commonly released from the PKS via hydrolysis or 
macrocyclization to give a linear or cyclic product, respectively. Chain release 
is usually catalysed by a thioesterase (TE) domain, which first loads the 
polyketide onto an active-site serine residue before offloading occurs. 
Offloading by macrocyclization, like for the 6-dEB PKS, proceeds via a high 
degree of regio- and stereo-selectivity. Combinatorial biosynthesis of PKSs, 
however, has demonstrated that these domains can be promiscuous towards 
unnatural substrates, simply hydrolysing the polyketide chain if 
macrocyclization is no longer feasible42. 
 
To introduce further structural diversity, polyketides often undergo a number 
of post-PKS modifications that are catalysed by standalone enzymes encoded 
for in the biosynthetic gene cluster (BGC). To obtain the active antibiotic 
erythromycin (4), biologically inactive 6-dEB (9) is subjected to glycosylation, 
with L-mycarose and D-desosamine, hydroxylation at two positions on the 
macrolide core and O-methylation of the L-mycarose moiety43. An extensive 
array of post-PKS modifications have been observed in the study of these 
systems, that are catalysed by a diverse range of enzymes, which include; 
oxidoreductases (that introduce hydroxy, epoxide, aldehyde and keto groups), 
reductases, glycosyltransferases, methyltransferases (in particular O-
methyltransferase), acyltransferases, aminotransferases, halogenases and 
cyclases. Unlike for the tailoring domains that are a part of the PKS, it is often 
not possible to predict accurately the action of the post-PKS enzymes. 
Elucidating the function and order in which these enzymes operate is often 
achieved through the creation of gene knockouts and characterisation of the 
resulting metabolite, thus the investigation of these enzymes has led to the 





1.2.2 Trans-AT PKSs 
 
 
Recently, a second type of modular PKS was identified, that was found to have 
evolved independently from cis-AT PKSs46. Trans-AT PKSs differ 
fundamentally from their cis-AT PKS counterpart by way of the activity of the 
AT domain, hence the chosen nomenclature. Trans-AT PKSs lack integrated 
AT domains and instead AT domain activity is provided in trans by a 
standalone AT domain, which acts iteratively to provide the extender unit to 




Figure 1.12: The module structure of trans-AT PKSs compared to cis-AT 
PKSs. 
 
Trans-AT domains are usually malonyl-CoA specific. Only one trans-AT 
domain has been experimentally characterised that was shown to accept a 
non-malonyl substrate; an AT domain from the kirromycin PKS was found to 
utilise ethylmalonyl-CoA47. It is proposed, however, that the oxazolomycin and 
etnangien pathways possess trans-AT domains that accept methoxymalonyl-
CoA and succinyl-CoA, respectively48,49. This is in huge contrast with the AT 
domains found in cis-AT PKSs, which have been shown to utilise a wide 
variety of starter and extender units (Figure 1.6). Many trans-AT PKS BGCs 
also encode for acyl hydrolase (AH) domains, that can commonly be found 
fused to the AT domain50. The AH domain from the pederin biosynthetic 
pathway was shown to hydrolyse a number of different ACP bound acyl units, 
however it did not cleave malonyl-ACP51. It is therefore proposed that these 
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domains play a proofreading role, removing stalled intermediates, during 
biosynthesis.  
 
Bacillaene (10), an unstable polyene diamine antibiotic, was isolated from 
Bacillus subtilis in 1995 and it was found to be biosynthesised by a trans-AT 
PKS, which was the first trans-AT PKS to be characterised (Figure 1.13)52. 
Due to the high density of non-canonical modules that often contain novel 
enzymatic domains in trans-AT PKSs, the principal of co-linearity can rarely 
be applied, and from the domain organisation alone it would not be possible 
to predict the structure of bacillaene (10). This PKS, however, had an 
interesting feature; stalled polyketide intermediates were hydrolytically 
released from the PKS. This gave an insight into the function of the many 





Figure 1.13: Pathway for bacillaene biosynthesis, showing the ACP-bound  
polyketide intermediates following a- and b-carbon processing. Black circles 
represent ACP domains. The b-branching cassette shown is responsible for 
introducing a b-methyl substituent to the growing polyketide chain in module 
5. C = condensation domain and A = adenylation domain.  
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1.2.2.1 Chain initiation mechanisms 
 
In trans-AT PKSs a diverse range of starter units are utilised, thus numerous 
different chain initiation mechanisms have been found. In the bacillaene 
biosynthetic pathway an acyl ligase (AL) domain is used to load the unusual 
a-hydroxy-isocaprotic acid starter unit onto the first ACP domain of the PKS54.  
AL domains can be found in a few trans-AT PKSs and they catalyse the 
adenosine triphosphate (ATP)-dependant thioesterification of an acid and an 
ACP domain55. These proteins show similarity to aromatic-acid- and long-
chain fatty-acid-CoA ligases56. 
 
The most commonly seen chain initiation mechanism in trans-AT PKSs utilises 
a GCN5-related N-acetyltransferase (GNAT) domain, which catalyses both the 
decarboxylation of malonyl-CoA to acetyl-CoA and the loading of the acetyl 
unit onto the first ACP domain of the PKS57. These domains can occasionally 
be observed in cis-AT PKSs, where they were first characterised57. Starter unit 
loading in cis-AT PKSs is almost exclusively catalysed by an AT domain. The 
AT domain either directly selects for a starter unit, or loads a typical extender 
unit, which is then decarboxylated by a KSQ domain. KSQ domains possess a 
mutation of the active site cysteine residue, to either glutamine or serine, 
meaning they are not capable of catalysing translocation, so act purely as 
decarboxylase58. A comparison of the most commonly used chain initiation 






Figure 1.14: The most commonly utilised chain initiation mechanisms by 
trans- and cis-AT PKSs. 
 
1.2.2.2 Non-elongating KS domains 
 
Four non-elongating KS domains (KS0), which are ubiquitous in trans-AT 
PKSs, can be found in the bacillaene PKS. KS0 domains simply translocate 
the growing polyketide from one ACP domain to the next. These KS domains 
possess a mutation of the conserved histidine residue, from the HGTGT motif, 
which is required for decarboxylative condensation46.   
 
1.2.2.3 Unusual domain architectures 
 
A huge number of module variants have been observed in trans-AT PKSs50. 
In the bacillaene biosynthetic pathway this is exemplified by the four different 
domain architectures used to install double bonds into the growing polyketide 
chain. The KS-DH-KR-ACP architecture is found in modules 4, 10 and 11 and 
incorporate double bonds into the growing polyketide chain, however, 
interestingly in modules 10 and 11 the a / b-double bond generated is 
migrated, giving a b / g-double bond. It is proposed that the DH domains in 
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these modules are likely responsible for the observed double bond topology50. 
A KS-DH-KR-MT-ACP module can also be found in the PKS, which generates 
a trans-double bond with an a-methyl branch. Two modules, modules 3 and 
6, are split across two PKS proteins; split modules are regularly observed in 
trans-AT PKSs. Both of these modules have the domain architecture KS-KR-
ACP-KS0 DH-ACP, which appear to divide reduction and dehydration into 
discrete steps. Interestingly, it seems that both of these modules install 
unusual cis-double bonds, although dehydration modules with this domain 
architecture have yet to be biochemically characterised50,53. The final module 
in the bacillaene PKS has the domain architecture KS-DH-KR-MT-ACP-KS0-
DH*-KS0-TE which also incorporates a b / g-double bond, but to achieve this 
the unusual enoyl-isomerase (DH*) domain is utilised59.  
 
1.2.2.4 Recruitment of unusual domains 
 
Many of the different domain architectures observed in trans-AT PKSs can be 
attributed to the inclusion of unusual domains, such as the DH* domain. The 
DH* domain is structurally related to DH domains, however the catalytic 
histidine is positioned differently, allowing the histidine residue to shuttle a 
proton from the g-position to the a-position, via the mechanism shown in Figure 
1.1560. The bacillaene PKS also recruits non-ribosomal peptide synthase 
(NRPS) domains to integrate the amino acids, glycine and alanine, into the 
growing polyketide chain. Like PKSs, NRPSs are large modular enzymes, 
however, they catalyse the condensation and modification of amino acid 
building blocks61. The condensation (C) and adenylation (A) domains found in 








Figure 1.15: Mechanism of double bond migration catalysed by the DH* 
domain. The catalytic histidine residue is indicated. R = polyketide chain. 
 
Trans-AT PKSs have also been found to utilise many other embedded 
processing domains during polyketide assembly, which are rarely observed in 
cis-AT PKSs. These include; pyran synthase domains that catalyse the 
formation of five- or six-membered oxygen containing rings, branching 
domains that are involved in the formation of glutarimide, lactam and d-lactone 
moieties, oxygenase domains and O-methyltransferase domains50.  
 
1.2.2.5 Introduction of methyl branches during chain assembly 
 
In trans-AT PKSs, methyl substituents are commonly incorporated into the 
polyketide chain during PKS assembly by either a dedicated C-
methyltransferase (CMT) domain or by a b-branching cassette that acts in 
trans50. Both of these mechanisms for methyl branch incorporation can be 
found in cis-AT PKSs, from where they have been characterised, however, 
they are found much less frequently owing to the use of methylmalonyl-CoA 
as an extender unit in these PKSs29.  
 
Embedded CMT domains, which can be found in modules 7 and 12 of the 
bacillaene PKS, catalyse the transfer of a methyl group from S-adenosyl 
methionine (SAM) to the a-position of the b-keto polyketide intermediate that 
is generated by chain elongation (figure 1.16)62. Biochemical studies on the 
CMT domain from the curacin A biosynthetic pathway (which was the first 
example of an embedded MT domain to be characterised) revealed that the 
CMT domain was not able to act upon a b-hydroxyl substrate, indicating that 
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a-methylation occurs prior to reductive modification of the polyketide 
intermediate62. It has also, recently, been shown that this reaction proceeds 





Figure 1.16: Mechanism of C-methylation catalysed by embedded CMT 
domains. The catalytic histidine residue is indicated. R = polyketide chain. 
 
Incorporation of a b-methyl branch in the growing polyketide chain requires a 
set of enzymes that act in-trans, which is usually encoded for in the BGC. The 
set of enzymes are commonly referred to as the b-branching cassette and 
usually consist of a standalone ACP and KS domain, a 3-hydroxy-3-methyl 
glutaryl-CoA synthase (HMGS) like enzyme and enoyl-CoA dehydratase 
(ECH) enzymes. To convert the b-keto moiety into a carbon branch, malonyl-
CoA is first loaded onto the standalone ACP domain where it is 
decarboxylated, by the KS domain, to give an acetyl unit. The HMGS enzyme 
then catalyses the aldol addition of the acetyl unit to the growing polyketide 
chain, before the aldol adduct is dehydrated and decarboxylated by the ECH 
enzymes to give a b-methyl branch (Figure 1.17)50. The location on the PKS 
where b-branching occurs can be predicted by the presence of a module that 
consists of a KS domain and two or more ACP domains, which is module 5 in 
the bacillaene PKS. It has been established that multiple ACP domains are 






Figure 1.17: General mechanism for the formation of b-branches in PKSs. The 





Gladiolin (11) is a novel macrolide antibiotic that was recently isolated from 
Burkholderia gladioli BCC0238 and is of particular interest as it demonstrates 
potent antimicrobial activity against Mycobacterium tuberculosis, a human 
pathogen that has received substantial attention in recent years due to the 
rapidly increasing prevalence of extensively drug resistant strains. It was found 
to have a minimum inhibitory concentration (MIC) of 0.4 µg/mL against M. 
tuberculosis H37Rv and was also discovered to be active against four M. 
tuberculosis clinical isolates that were resistant to isoniazid and one that was 
resistant to both isoniazid and rifampicin (5)65. Like rifampicin (5), gladiolin (11) 
was found to inhibit bacterial RNA polymerase, however the precise mode of 
action has yet to be established65. 
 
Gladiolin (11) is structurally similar to etnangien (12), which is an antibiotic that 
also demonstrates potent antimicrobial activity by efficiently inhibiting RNA 
polymerases (Figure 1.18). It was isolated from Sorangium cellulosum SO 
ce750 in 200766.  Etnangien (12) is a highly unstable antibiotic due to its 
Introduction 
 24 
hexene moiety which is prone to light induced isomerisation and oxidative 
degradation48. Attempts were made to identify the pharmacore of etnangien 
(12); a series of analogues were synthesised that included the macrolide core 
with truncated side chains and a series of side chains without the macrolide 
moiety, however, none of these analogues demonstrated antimicrobial 
activity67,68. It was, thus, concluded that both the macrolide core and side chain 
were essential for its pharmacological activity so development of etnangien 
(12) for clinical use was not pursued. The discovery of gladiolin (11), however, 
strongly suggests that modifications can be made to the side chain of these 
antibiotics without detriment to bioactivity, making gladiolin an attractive 





Figure 1.18: The structure of gladiolin and etnangien. The differing side 
chains are highlighted in purple. 
 
The gladiolin BGC was identified using a combination of single-molecule real-
time based genome sequencing and targeted mutagenesis (Figure 1.19). The 
proposed function of each of the non-PKS proteins encoded for by the BGC 
are listed in Table 1.165. It was established that gladiolin is biosynthesised by 
a trans-AT PKS, consisting of six PKS proteins, which exhibits many of the 
functional peculiarities associated with this class of PKS; the proposed 
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biosynthesis is shown in Figure 1.2065. Firstly, it is proposed that the gladiolin 
PKS contains three non-elongating KS domains, as there are twenty KS 
domains, while only seventeen chain elongations are required to construct 
gladiolin. Interestingly, none of the KS domains found in the gladiolin PKS are 
true KS0 domains, as they all possess the histidine residue that is required for 
catalysing chain elongation, which is normally mutated. Based on the structure 
of gladiolin (12) and the PKS domain architecture, it was tentatively 
hypothesised that KS domains 12, 14 and 20 are non-elongating65. When 
comparing the structure of gladiolin to the domain architecture it is also 
apparent that modules 5 and 10 of the PKS lack the expected ER domains, 
however it has recently been shown that a standalone ER domain, GbnE, is 
responsible for catalysing enoyl-reduction in both of these modules in the 
gladiolin PKS69. Furthermore, module 11 of the PKS contains an unusual 
embedded O-methyltransferase (OMT) domain. Embedded OMT domains are 






























gbnA/GbnA 264/88 Hypothetical protein: Sorangium 
cellulosum (60 %) 
Acyl carrier protein: Streptomyces rimosus 
(49 %) 
gbnB/GbnB 894/298 Malonyl-CoA-ACP transacylase: 
Sorangium cellulosum (54 %) 
Hypothetical protein: Desulfovibrio 
inopinatus (46 %) 
gbnC/GbnC 1968/656 Asparagine synthetase: Sorangium 
cellulosum (65 %) 
Asparagine synthetase: Labrenzia alba 
(51 %) 
gbnE/GbnE 1389/463 Permease: Sorangium cellulosum (68 %) 
ER domain BatK: Pseudomonas 
fluorescens (60 %) 
gbnF/GbnF 246/82 Acyl carrier protein: Sorangium cellulosum 
(68 %) 
Hypothetical protein: Paenibacillus 
pinihumi (59 %) 
gbnG/GbnG 1212/404 Polyketide beta-ketoacyl-ACP synthase: 
Sorangium cellulosum (65 %) 
Polyketide beta-ketoacyl-ACP synthase: 
Pelonsinus fermentans (57 %) 
gbnH/GbnH 1260/420 3-hydroxy-3-methylglutaryl-ACP synthase: 
Sorangium cellulosum (99 %) 
3-hydroxy-3-methylglutaryl-ACP synthase: 
Sorangium cellulosum (76 %) 
gbnIIGbnI 789/263 Enoyl-CoA hydratase/isomerase: 
Sorangium cellulosum So ce56 (63 %) 
Enoyl-CoA hydratase: Paenibacillus tyrfis 
(57 %) 
gbnJ/GbnJ 747/249 Enoyl-CoA hydratase: Sorangium 
cellulosum (99 %) 
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Enoyl-CoA hydratase BatE: Pseudomonas 
fluorescens (60 %) 
gbnK/GbnK 3234/1078 Hypothetical protein SorM: Sorangium 
cellulosum (99 %) 
Hypothetical protein: Sorangium 
cellulosum (99 %) 
gbnL/GbnL 360/120 Alpha/beta hydrolase: Burkholderia 
glumae (74 %) 
Alpha/beta hydrolase: Sorangium 
cellulosum  (58 %) 
GbnM/GbnM 1401/467 Amidase: Sorangium cellulosum (56 %) 
Amidase SorP: Sorangium cellulosum  
(46 %) 
gbnN/GbnN 1185/395 Malonyl-CoA-ACP transacylase: 
Methylococcaceae bacterium (53 %) 
Malonyl-CoA-ACP transacylase: 
Scytonema sp. PCC 10023 (48 %) 
gbnO/GbnO 849/283 4’-phosphopantetheinyl transferase: 
Collimonas arenae (47 %) 
Hypothetical protein: Janthinobacterium 
sp. CG3 (44 %) 
gbnP/GbnP 975/325 Malonyl-CoA-ACP transacylase: 
Burkholderia thailandensis (53 %) 
Malonyl-CoA-ACP transacylase: 
Xanthomonas cannabis (50 %) 
gbnQ/GbnQ 1353/451 Multidrug transporter MatE: 
Chromobacterium subtsugae (72 %) 
Multidrug transporter MatE: Sorangium 
cellulosum (68 %) 
gbnR/GbnR 792/264 Enoyl-CoA hydratase: Burkholderia 
glumae (89 %) 
Enoyl-CoA hydratase: Burkholderia 
plantarii (86 %) 
gbnS/GbnS 1206/402 Enoyl-CoA hydratase: Burkholderia 
glumae (83 %) 
Enoyl-CoA hydratase: Burkholderia 







Figure 1.20: Proposed pathway for gladiolin biosynthesis, showing the ACP-
bound predicted polyketide intermediates following a- and b-carbon 
processing. Black circles represent ACP domains. The domain with a cross 
through it indicates that the domain lacks the key catalytic residues required 
for activity. The b-branching cassette shown, is responsible for introducing b-
methyl substituents to the growing polyketide chain in modules 1 and 6. 
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Phylogenetic analysis of the AT domains encoded for by the gladiolin BGC 
indicated that GbnN was an AT domain with specificity for the extender unit 
malonyl-CoA, whereas the AT domain GbnB claded separately from the 
malonyl-specific AT domains. It was therefore proposed that this unusual AT 
domain may show specificity for the hypothesised starter unit, succinyl-CoA65. 
Genes for a HMGS cassette were also identified in the gladiolin BGC, with two 
sets of ECH enzymes encoded for, which are responsible for the incorporation 
of b-methyl branches in modules 1 and 6, via the mechanism described in 
section 1.2.2.5. Additionally a number of putative auxiliary genes were 
identified in the gladiolin BGC. The role of two genes in particular, gbnC which 
encodes for a putative asparagine synthetase and gbnM which encodes for a 
putative amidase, is esoteric owing to the fact that gladiolin contains no 
nitrogen atoms. 
 
The aim of this study is to investigate some of the unusual features of gladiolin 
biosynthesis, namely the O-methylation module with the dedicated OMT 
domain, found in module 11 of the PKS, and the role of the cryptic auxiliary 
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Chapter 2 
 
O-methylation during chain 




This work is in collaboration with Christian Hobson, University of Warwick, 




Trans-AT PKSs have been noted to contain O-methylation modules that have 
a dedicated OMT domain, however these modules remain one of the 
peculiarities of trans-AT systems that have yet to be characterised50. The 
example found in the gladiolin biosynthetic pathway is shown in Figure 2.1. It 
is proposed that these modules consist of two parts, with the first part 
catalysing chain elongation and reduction of the diketo-intermediate to 
generate a b-hydroxyl moiety, so that methylation can then occur on the 
second non-elongating segment.  
 
O-methylation is commonly found as a post-PKS tailoring step, with the 
location of methylation dictated by the structure of the resultant polyketide. 
These enzymes often show narrow substrate specificity and there are few 
reported examples where the substrate promiscuity has been successfully 
expanded by rational engineering70,71. Embedded OMT domains could provide 
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an alternative approach to engineering methylation, where the position of 





Figure 2.1: A closer look at the O-methylation module from the gladiolin 
biosynthetic pathway. The proposed sequence of enzymatic reactions is 
shown, with methylation hypothesised to occur on the second non-elongating 
part of the module. The domains involved in each step are highlighted, with 
the hypothesised non-elongating KS domain shown in grey. R = polyketide 
chain.  
 
The aim of this study is to gain full insight into O-methylation modules for the 
prospective of bioengineering, which requires knowledge of the substrate 
tolerance and structure of the OMT domain as well as an understanding of the 
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2.2 In-vitro reconstitution of embedded OMT domain activity 
 
2.2.1 Purification and characterisation of GldM11OMT-ACP 
 
In order to study the activity of the OMT domain from the gladiolin biosynthetic 
pathway a synthetic pET24a construct of the OMT-ACP didomain was 
designed based upon the domain boundaries determined by antiSMASH 2.0, 
a web-based tool that is able to analyse PKS domain architecture72. This was 
used to heterologously overproduce GldM11OMT-ACP as an octa-histidine 
tagged protein, that was purified by nickel affinity chromatography. An octa-
histidine tag was chosen as it has been shown to result in increased protein 
purity, when compared with the more commonly used hexa-histidine tag, as 
more stringent wash conditions can be used due to an increased binding 
strength to the nickel column73. SDS-PAGE analysis showed the protein was 
pure and of the expected molecular weight (Figure 2.2 (A)), which was 
confirmed by intact protein mass spectrometry (MS) (Appendix 1). Size 
exclusion chromatography showed that the protein was monomeric in solution 




Figure 2.2: (A) 10 % SDS-PAGE gel showing purified GldM11OMT-ACP. (B) 
A graph showing the results of size exclusion chromatography for 
GldM11OMT-ACP. 
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2.2.2 Methylation assay design 
 
A one-pot methylation assay was designed and optimised to demonstrate that 
the excised didomain was catalytically active in vitro (Figure 2.3 (A)). 
Simplified pantetheine analogues of the predicted substrate for the OMT 
domain were chemo-enzymatically converted to the associated CoA 
derivatives (Figure 2.3 (B))74. This method utilised enzymes from the E. coli 
CoA biosynthetic pathway; first pantothenate kinase (PanK) was used to 
phosphorylate the substrate mimic so that phosphopantetheine 
adenyltransferase (PPAT) could then catalyse the adenylylation to generate 
dephospho-CoA analogues. A final phosphorylation was carried out by 
dephosphocoenzyme A kinase (DPCK) producing CoA substrates, that the 4’-
phosphopantetheinyl transferase (Sfp) could load onto the conserved serine 
residue of the ACP domain (as shown in Figure 1.4). 4’-phosphopantetheinyl 
transferases were found to demonstrate promiscuity towards their CoA 
substrate and the ACP domain being modified, making them a useful tool for 
the biochemical studies of PKSs75. 
 
The holo-protein was incubated with SAM, the biologically abundant cofactor 
that is essential for methylation, for 1 hour (h) 30 minutes (min).  Longer 
incubation times resulted in minimal increase in observed methylation and also 
significantly reduced the quality of the MS data due to degradation of the 
protein. High-resolution intact protein MS, a tool which has been extensively 
used in the study of PKSs, was chosen as a means of monitoring the outcome 
of the methylation assays, as this technique can accurately detect biosynthetic 
transformations that involve small mass changes, from minimal amounts of 
protein76.  
 




Figure 2.3: (A) Overview of the methylation assays conducted. (B) The 
enzymatic reactions that were used to convert the pantetheine substrates to 
CoA analogues. 
 
2.2.3 Confirming the in-vitro activity of GldM11OMT-ACP 
 
Initially, the very simple substrate mimic 3-hydroxybutyryl-ACP was used to 
assess whether the excised didomain was catalytically active in vitro, however 
it was found that this was not a substrate for the OMT domain (Figure 2.4 (A)). 
It was then decided to see if the longer-chain substrate mimic 3-
hydroxyoctanoyl-ACP would be accepted. Selective methylation of the S 
stereo-configured b-hydroxyl group was observed, which was expected given 
that sequence analysis of the KR domain from module 11 indicated that this 
would be the stereochemistry of the hydroxyl group generated in vivo65 (Figure 
2.4 (A)). Methylation was determined by the presence of a peak in the 
deconvoluted MS spectrum corresponding to a mass increase of 14 Da that 
was not seen in the absence of SAM (Figure 2.4 (B)). A peak could also be 
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observed in both the reaction and control experiments corresponding to the 
loss of water (-18 Da); loss of water is commonly seen during the MS of 
secondary alcohols. The MS of holo-ACP proteins leads to the ejection of the 
phosphopantetheine arm from the protein preserving the thioester bond to the 
substrate77. The identification of these fragment ions further confirmed that 




Figure 2.4: (A) Stacked deconvoluted ESI-MS spectra of GldM11OMT-ACP 
with ACP bound simplified substrate mimics after incubation with SAM. The 
spectrum where methylation (+14 Da) was observed is highlighted in purple. 
(B)  A closer look at the deconvoluted spectrum for the (S)-3-hydroxyoctanoyl 
substrate mimic. (C) Spectrum showing the key phosphopantetheine ejection 
ions for the (S)-3-hydroxyoctanoyl substrate mimic. 
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In order to investigate whether the OMT domain showed regioselectivity 
towards hydroxyl groups at the b-position, the methylation assay was 
conducted using 3,5-dihydroxyhexanoyl substrates. Only mono-methylation 
was observed for the (3S,5S)-3,5-dihydroxyhexanoyl-ACP substrate (Figure 
2.5 (A)). The fact that only mono-methylation was observed suggested that 
the OMT domain was not capable of carrying out methylation of a d-hydroxyl 
group, and did indeed shows regioselectivity for b-hydroxyl groups. 
Unfortunately, data could not be obtained for the (3S,5R)-3,5-
dihydroxyhexanoyl- and (3R,5S)-3,5-dihydroxyhexanoyl-ACP substrates due 
to lactonization occurring, which resulted in the loss of the substrate bound to 
the ACP domain. Lactonization is more rapid for the anti-diols as the reaction 















Figure 2.5: (A) Stacked deconvoluted ESI-MS spectra of GldM11OMT-ACP 
with the 3,5-dihydroxyhexanoyl ACP bound substrate mimics after incubation 
with SAM. Highlighted in purple is the only spectrum where methylation (+14 
Da) was observed. (B) Mechanism of lactonization of the 3,5-
dihydroxyhexanoyl substrates, the transition states are shown. Lactonization 
is faster for the anti-diols as the reaction proceeds via a more favourable 
transition state that has both substituents in the equatorial position. 
 
2.3 Identification of key catalytic residues 
 
2.3.1 Sequence alignment 
 
ClusterTools, a bioinformatics tool that enables facile searching of genomes 
for functional elements in close proximity to each other78, was used to find 
additional examples of embedded OMT domains from trans-AT PKSs. A 
database constructed of BGCs from the MiBIG repository79 was searched 
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using a custom HMM rule looking for genes that contained an OMT domain, a 
PKS KS domain and not a PKS AT domain. It was found that when using the 
default parameters, OMT domains were not able to be distinguished clearly 
from CMT domains, so the HMM search E-value was made substantially 
smaller, so that the returned matches would be more significant. Having been 
able to identify embedded OMT domains in known BGCs using clusterTools, 
a search was then ran, using the same settings, on a database containing all 
reference and representative bacterial genomes from NCBI. This did reveal 
some cryptic clusters that appear to contain embedded OMT domains, 
however, in all cases the sequence data was too poor to be able to make any 
predictions about the products of these clusters. In total 9 additional, 
characterised trans-AT PKSs were found to contain embedded OMT domains, 
with some pathways utilising more than one embedded OMT domain; the 
secondary metabolites for the identified pathways are shown in Figure 2.648,80–
85.  
 
In order to identify any conserved residues that may play a key role in 
catalysis, a sequence alignment was created (Appendix 2). The sequence 
alignment, along with comparison to the patellazole and luminaolide OMT 
domains, that sit respectively at the beginning and end of a PKS gene, 
improved the approximation of the domain boundaries. The sequence 
alignment showed the expected highly conserved C-terminal GxGxG motif that 
is considered to be the hallmark SAM-binding region86, and also revealed a 
second region of high sequence conservation, that is a strong candidate to be 















Figure 2.6: The structure of secondary metabolites produced by trans-AT 
PKSs that utilise embedded OMT domains during chain assembly, the O-
methyl groups installed by these domains are shown in purple. The titles of 
natural products derived from marine microorganisms are shown in blue.  
 




Figure 2.7: Sequence logo, constructed using WebLogo, of a sequence 
alignment of all reported embedded OMT domains from trans-AT PKSs, 
showing the conserved histidine residue proposed to be the key catalytic 
base. The height of each amino acid indicates the sequence conservation at 
that position. Basic residues are shown in purple and acidic residues in blue.  
 
The conserved active site motif contained a completely conserved histidine 
residue. SAM-dependant OMTs commonly use histidine, and other basic 
residues, to deprotonate and thus activate the hydroxyl group for nucleophillic 
attack on the methyl group of SAM87, hence this is the likely role of His153  in 





Figure 2.8: The proposed mechanism for SAM dependent methylation in 
trans-AT embedded OMTs, • represents the ACP domain. It is not known 
whether proton transfer happens prior to, or in concert with the transfer of the 
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2.3.2 Investigating the activity of GldM11OMT-ACP(H153A) 
 
To probe the role of His153, the residue was mutated to alanine using site-
directed mutagenesis. The successful creation of the mutant was confirmed 
by sequencing and the detected mass change of the resultant protein, 
GldM11OMT-ACP(H153A) (Appendix 1). The activity of GldM11OMT-
ACP(H153A) was evaluated using the methylation assay discussed in section 
2.2.2 and no methylation was observed (Figure 2.9). This confirms that this 
histidine residue is important for catalysis, and also provides an important 
control reaction to ensure that the observed methylation by GldM11OMT-ACP 




Figure 2.9: Stacked deconvoluted ESI-MS spectra of GldM11OMT-(S)-3-
hydroxyoctanoyl-ACP (A) and GldM11OMT-(3S,5S)-3,5-dihydroxyhexanoyl-
ACP (B) after a 1 h 30 min incubation with SAM. GldM11OMT-ACP WT is 
represented in purple and GldM11OMT-ACP(H153A) is shown in grey. A 
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2.4 Structural studies 
 
2.4.1 Crystallisation trials 
 
In order to gain further understanding of the active site of embedded OMT 
domains it was hoped that a crystal structure could be obtained. Structural 
knowledge of domains is an invaluable tool for prospective PKS engineering, 
with a thorough understanding of protein interfaces and well defined domain 
junctions imperative for success88. As the domain boundaries for the gladiolin 
OMT domain were only approximate (based on AntiSMASH predictions), 6 
constructs with various N- and C-termini were created to try and ascertain 
more precise domain boundaries, which are required for protein 
crystallography. The N- and C-termini were chosen based on protein 
secondary structure predictions made by Phyre2 89. The constructs were 
created by cloning the appropriate regions of DNA, that were amplified by PCR 
from the pET24a-GldM11OMTACP vector, into the pET28a expression vector 
using traditional cloning methods. The resultant constructs were tested for the 
production of soluble protein and only one construct yielded soluble protein, 
GldM11OMT. It is likely that the other proteins were insoluble due to the 
chosen domain boundaries disrupting secondary structure, which would 
prevent the correct folding of the protein.  
 
GldM11OMT was heterologously overproduced on a large scale and purified 
by both nickel-NTA chromatography and size exclusion chromatography 
(SEC), as a high level of protein purity was required for crystallography. SDS-
PAGE analysis showed that the protein was pure and of the correct molecular 
weight (Figure 2.10), which was confirmed by intact protein MS (Appendix 1). 
Proteins overproduced using pET28a constructs undergo N-terminal 
methionine excision and gluconoylation of the histidine-tag, which could be 
detected in the deconvoluted MS spectra90,91. The activity of this excised OMT 
domain was demonstrated and the results can be found in section 2.7. 





Figure 2.10: 8 % SDS-PAGE gel showing the purified proteins that were used 
for structural studies. The domain architecture of the proteins is shown above 
the corresponding lane. 
 
In an attempt to identify conditions that would yield crystals, 7 commercial 
crystallisations screens were utilised, meaning a variety of pH values, 
precipitant types and concentrations, as well as different temperatures were 
tested, however no crystals were obtained. The reason why proteins do not 
crystallise can be elusive, but it is often found that conformational stability of 
the protein is paramount92. For this reason the crystallisation trials were 
repeated using GldM11OMT with the polyhistidine-tag removed as well as the 
KS-OMT didomain, GldM11KS-OMT. KS domains from PKSs are dimeric and 
have been demonstrated to crystallise well93–97 so it was hoped the presence 
of this domain would bring additional stability to OMT domain. Unfortunately 
no conditions were identified that produced protein crystals.  
 
2.4.2 Homology modelling 
 
As a crystal structure could not be obtained a homology model was generated 
using the intensive modelling mode of Phyre2 89. The quality of the model was 
assessed by generating a Ramachandran plot using RAMPAGE software 
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which revealed that of the 350 residues, 315 were in the favoured region (89.4 
%), 22 were in an allowed region (6.3 %) and 15 were in the disallowed region 
(4.3 %) indicating that the predicted model was not good (Appendix 3). This 
was not unsurprising given that of the six templates used to build this model 
the maximum sequence identity was 19 %. A homology model is considered 
to be good, if a template sequence is used that has at least 30 % sequence 
identity to the queried sequence98, however, literature examples of SAM-
dependant MTs share very little sequence identity, but incorporate a highly 
conserved structural fold99. The homology model suggests that like the 
majority of SAM-dependant MTs, embedded OMT domains from trans-AT 
PKSs belong to the class I MT superfamily. Class I MTs are characterised by 
alternating a-helices and b-sheets that come together to form a Rossmann-
like fold that comprises of a seven-stranded b-sheet flanked by 3 a-helices on 




Figure 2.11: Homology model of GldOMT generated using the intensive mode 
of Phyre2. (A) Overall model with the defining class I MT fold shown in purple. 
(B) Close up showing the proximity of the proposed key catalytic histidine 
(purple) to SAH (teal). Images were created using PyMOL100. 
 
Little information can be gained from this model about substrate binding due 
to the lack of a good template; unsurprisingly this region varies greatly due to 
the wide range of substrates class I MTs act upon. Interestingly the model 
does place the identified key catalytic histidine in close proximity to the sulphur 
of SAH (Figure 2.11 (B)) which would be required for initiating methyl transfer. 
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2.5 Phylogenetic analysis 
 
A phylogenetic tree of all embedded OMT domains from known BGCs that 
were predicted by ClusterTools, and a number of post-PKS tailoring OMTs for 
which the biosynthetic role has been proven, was generated using ClustalX101 




Figure 2.12: Phylogenetic tree of OMT domains from modular type I PKSs. 
Embedded OMT domains are highlighted, with those found in trans-AT PKSs 
shown in purple and those from cis-AT PKSs shown in blue. Where clades 
are identified the conserved domain architecture is shown.  
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Embedded OMT domains claded separately to post-PKS tailoring enzymes 
with the phylogenetic analysis suggesting that once an OMT domain was 
recruited into a PKS all other embedded OMT domain containing PKSs 
evolved from this. There are two interesting exceptions that provide potential 
insight into the evolution of these domains, chondrochloren and soraphen, 
however the role of these OMT domains has yet to be experimentally 
demonstrated. In the biosynthesis of chondrochloren the OMT domain is found 
at the end of one of the PKS genes and is hypothesised to act across two 
modules; comparison to similar clusters suggest that this arose from the fusion 
of an ancestral discrete OMT domain102. The BGC for soraphen contains a 
unique protein that is comprised of an AT, ACP and OMT domain that is 
proposed to be responsible for the synthesis of the unusual extender unit 
methoxymalonyl-CoA103.  
 
Cis-AT PKSs containing embedded OMT domains have been identified 
exclusively in gram-negative bacteria104–113, from which biosynthetic pathways 
incorporating novel or atypical features are often found114. These OMT 
domains form two clades based upon whether a KR domain is present within 
the methylating module. When present it is predicted that the β-hydroxyl 
substituent generated will be the substrate for the OMT domain (Clade III). 
Where there is no KR domain it is hypothesised that the OMT domain gives 
rise to methylation of the enol form of the β-keto intermediate (Clade IV). Clade 
IV further splits based upon whether the thermodynamically more stable trans-
isomer, or the cis-isomer, is formed. 
 
The trans-AT embedded OMT domains also split into two distinct clades, 
however the reason for this is not apparent. They do not appear to clade based 
upon surrounding domain architecture or any features of the hypothesised 
substrates such as stereochemistry of the methylated b-hydroxyl group, 
substrate length or the presence of a-, g- or d- substituents (Figure 2.13). 
 




Figure 2.13: The hypothesised substrates for the embedded OMT domains 
from trans-AT PKSs. For PKSs that contain more than one embedded OMT 
domain the module containing that OMT domain is indicated. 
 
2.6 Comparing the substrate tolerance of embedded OMT 
domains from two different clades 
 
As the phylogenetic analysis revealed that embedded OMT domains from 
trans-AT PKSs form two undefined clades, the substrate tolerance of three 
additional embedded OMT domains, two from the misakinolide PKS80 and one 
from the rhizopodin PKS85, was explored in an attempt to shed light upon this. 
The MisM9OMT domain clades with the GldM11OMT domain (clade II), whilst 
the MisM1OMT domain clades with the RizM18OMT domain (clade I). The 
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DNA sequences of these OMT-ACP didomains were obtained from the MIBiG 
repository79, and were purchased as synthetic DNA fragments (GenScript) that 
were cloned into the pET28a expression vector. A pET24a-MisM1OMTACP 
synthetic construct (purchased from Epoch Life Sciences) was used for the 
overproduction of MisM1OMTACP. The corresponding proteins were 
overproduced as histidine-tagged proteins and purified by Ni-NTA 
chromatography. SDS-PAGE analysis showed that all of the proteins were of 
high purity and of the predicted size (Figure 2.14), which was confirmed by 




Figure 2.14: 10 % SDS-PAGE gel showing the purified proteins, MisM9OMT-
ACP (represented in pink), MisM1OMT-ACP (represented in dark purple) and 
RizM18OMT-ACP (represented in blue). 
 
A summary of the results from the methylation assays carried out, as 
discussed in section 2.2.2, is shown in Figure 2.15 and the supporting 
methylation data can be found in Appendix 4. The data suggests that substrate 
tolerance is something that is unique to each individual OMT domain and thus 
unlikely to be a contributing factor towards the formation of the two clades. 
The MisM1OMT domain demonstrated stereoselectivity towards the 
methylating hydroxyl group up until the substrate tested became longer than 
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the natural substrate (shown in Figure 2.13), which interestingly was still 
accepted as a substrate by the OMT domain. The other two characterised 
OMT domains did not demonstrate any clear preference for one stereo-
configured hydroxyl group over the other, although MisM9 would only accept 
its proposed natural stereoisomer when a 4-carbon chain substrate was used. 
Given that the KR domain found within each methylation module would 
generate this hydroxyl group in a stereospecific manner there would be no 
evolutionary pressure on the OMT domain to demonstrate selectivity for 
efficient biosynthesis. The RizM18OMT domain showed no activity for the 
substrates tested that had a shorter chain length than 8 carbons, however it 
cannot be determined from the experiments carried out whether the 
dihydroxyhexanoyl substrates were not methylated due to the chain length, or 
because the OMT domain could not accept substrates with a d-hydroxyl group. 
 
In general the studied domains have demonstrated useful substrate 
promiscuity. The MisM9OMT stands out as the best candidate for future 
bioengineering as it accepts a range of short substrate mimics used in this 
study despite the fact that in vivo the substrate for this domain is substantially 
longer (see Figure 2.13) suggesting that it would be capable of methylating a 
wide range of chain lengths. This OMT domain also showed a lack of 
stereoselectivity towards the hydroxyl group being methylated meaning 
theoretically it could be placed after any KR domain in a PKS pathway, and  
demonstrated a tolerance for substrates with d-hydroxyl groups, of both 
stereochemistries, which is a feature often found in growing polyketide chains. 
For completion it would be interesting, in the future, to determine if this domain 
can also tolerate substrates with both a- and g-substituents.  
 
 




Figure 2.15: A summary of the substrate tolerance determined for several 
embedded OMT domains from trans-AT PKSs. Substrates accepted by the 
OMT domain are shown in bold and the predicted site of methylation is 
indicated. For the substrates shown in blue it is unclear if they can be 
methylated by the OMT domain as the substrates were lost from the protein 
due to lactonization. 
 
2.7 ACP domain specificity and the role of the KS0 domain 
 
2.7.1 The role of the KS0 domain 
 
In trans-AT PKSs embedded OMT domains are always found with 
hypothesised KS0 domains, that are predicted to translocate the growing 
polyketide chain from one ACP domain to another, so that O-methylation can 
occur (see Figure 2.1). The need for this suggests that there is a unique 
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interaction required between an OMT domain and an ACP domain for catalytic 
activity.  
 
In the gladiolin PKS this KS domain is not a true KS0 by definition, as it lacks 
the associated mutation of the histidine residue needed to catalyse chain 
elongation46, however the surrounding residues in the usually conserved 
HGTGT motif are mutated to HSVGS. These surrounding mutations along with 
the fact that the gladiolin PKS contains no true KS0 domains, but has 3 surplus 
KS domains when considering the number of chain elongations required to 
assemble gladiolin, has led to the prediction that this KS domain acts only as 
a transacylase65.  
 
In order to demonstrate the transacylation activity of this KS domain in vitro, 
both of the ACP domains from the gladiolin O-methylation module, 
GldM11ACP(I) and GldM11ACP(II), were cloned into pET28a, heterologously 
overproduced in E. coli and purified to homogeneity by nickel affinity 
chromatography. SDS-PAGE analysis showed that both of these proteins 
were pure and of the correct molecular weight (Figure 2.16), which was 




Figure 2.16: 15 % SDS-PAGE gel showing the purified ACP domains used in 
this study. 
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To demonstrate transacylation activity of the KS domain, GldM11ACP(I) was 
first loaded with (S)-3-hydroxyoctanoyl-pantetheiene as described in section 
2.2.2. GldM11ACP(II) was also converted to the holo-form by incubating the 
protein with Sfp and CoA. The resultant holo-ACP domains were then 
incubated with the GldM11KSOMT didomain (refer to section 2.4.1) for 3 h. 
Intact protein MS analysis of the assay revealed that in the presence of the 
GldM11KSOMT didomain the (S)-3-hydroxyoctanoyl moiety was offloaded 
from GldM11ACP(I), and partial transfer to GldM11ACP(II) could be observed 
(Figure 2.17). In the absence of the GldM11KSOMT didomain negligible 
transfer was seen. This strongly suggests that the KS domain is capable of 
catalysing translocation, however, to confirm that the KS domain is 
responsible for the observed transfer, this assay will need to be conducted 
with a GldM11KSOMT variant, where the KS domain active site cysteine 




Figure 2.17: Stacked deconvoluted ESI-MS spectra of GldM11-(S)-3-
hydroxyoctanoyl-ACP(I) and holo-GldM11ACP(II) after incubation with and 
without the GldM11KSOMT didomain. The data shows that the 
GldM11KSOMT didomain is able to catalyse the transfer of the (S)-3-
hydroxyoctanoyl moiety from GldM11ACP(I) to GldM11ACP(II). 
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2.7.2 ACP domain specificity in the gladiolin O-methylation module 
 
In order to determine if a specific interaction could be observed between the 
GldM11OMT domain and the second ACP domain from the gladiolin 
methylation module, an assay was conducted where both of the ACP domains 
from the methylation module, loaded with the (S)-3-hydroxyoctanoyl 
pantetheine substrate (see section 2.2.2), were incubated in turn with 
GldM11OMT in the presence of SAM and the S-adenosylhomocysteine (SAH) 
nucleosidase, Pfs, that prevents potent inhibition of the OMT domain by 
SAH115. Pfs was included as this assay relies on the OMT domain being able 
to conduct several catalytic cycles. In each case an excess of the OMT domain 
was used to account for the fact that the intermolecular interactions of the 
assay will be less efficient than the intramolecular interactions of the native 
system. The results are presented in Figure 2.18. 
 
Intact protein MS analysis of the assay showed that O-methylation was only 
able to occur on the second ACP domain of the methylating module, 
establishing the fact that a specific interaction between an ACP domain and 
OMT domain is required for methylation. Methylation was not observed for the 
first ACP domain even when the ratio of ACP domain to OMT domain was 
increased to 1:4, respectively, which eliminates any potential bias that could 
occur due to any error in the calculated protein concentrations. This observed 
ACP domain specificity provides evidence towards this being the reason for 
incorporation of a non-elongating KS domain as part of the O-methylation 
module.  
 




Figure 2.18: Stacked deconvoluted ESI-MS spectra of (S)-3-hydroxyoctanoyl-
ACP domains from the gladiolin methylation module, after incubation with 
GldOMT. Methylation (+ 14 Da) is only observed for ACP(II). Peaks marked 
with an * show the his-tag gluconoylated protein. 
 
2.7.3 ACP domain crosstalk 
 
To assess the ability of the GldOMT domain to interact with the ACP(II) 
domains from the other O-methylation modules looked at in this study, the 
ACP(II) domains were first cloned into pET28a, heterologously overproduced 
and purified by nickel affinity chromatography. SDS-PAGE analysis showed 
that the ACP domains were pure and of the correct molecular weight (Figure 
2.16), which was confirmed by intact protein MS (Appendix 1). The crosstalk 
assays were conducted as described in section 2.7.2 and the results of the 
analysis of the assays by intact protein MS are presented in Figure 2.19. 
 




Figure 2.19: Stacked deconvoluted ESI-MS spectra of (S)-3-hydroxyoctanoyl-
ACP(II) domains, after incubation with GldOMT. Methylation (+ 14 Da) is only 
observed for GldM11ACP(II) and MisM9ACP(II). Peaks marked with an * are 
from the gluconoylated protein and those marked with a ▲ are due to the loss 
of water. 
 
The crosstalk assays revealed that the GldOMT domain was only able to 
methylate the (S)-3-hydroxyoctanoyl substrate when bound to its cognate 
ACP(II) domain or the MisM9ACP(II), which is an ACP domain associated with 
an embedded OMT domain from the same clade, clade II. No methylation was 
observed for the two ACP domains associated with OMT domains from clade 
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I (even with a 1:4 ratio of ACP domain to OMT domain). This suggested that 
two different methods of communication could exist between embedded OMT 
domains and ACP domains.  
 
To investigate this further the MisM1OMT domain was cloned into pET28a, 
heterologously overproduced and purified to homogeneity by nickel affinity 
and SEC chromatography (SDS-PAGE analysis and intact protein MS data 
can be found in Appendix I). The crosstalk assays were then repeated for this 
OMT domain from clade I, and the results are shown in Figure 2.20. The 
assays were conduct using (R)-3-hydroxyoctanoyl-pantetheiene as the 
substrate, as the MisM1OMT domain utilises an R-configured alcohol as its 
natural substrate. The MisM1OMT domain was able to methylate this 
substrate when bound to all of the ACP domains. Furthermore, for the ACP 
domains from clade I OMT domains, methylation was also observed in the 
control reaction where no SAM was added. This indicates that the MisM1OMT 
domain retained some SAM in the active site during protein purification. The 
fact that methylation was observed in the control reaction for these ACP 
domains and not in the control reaction for ACP domains from clade II OMT 
domains suggests that a weaker interaction exists between the MisM1OMT 
domain and ACP domains associated with OMT domains from the other clade. 
 
Overall the crosstalk assays suggests that two different methods of 
communication exist between embedded OMT domains and ACP domains 
and that this contributes to the formation of the two clades. As the two different 
clades were revealed through analysis of the sequence of the OMT domains 
alone, it is likely that some structural variations exist between the OMT 
domains from the two clades that facilitate the different interactions, however 
a crystal structure of an OMT domain from each of the clades will be needed 
to confirm this. 
 




Figure 2.20: Stacked deconvoluted ESI-MS spectra of (R)-3-hydroxyoctanoyl-
ACP(II) domains, after incubation with MisM1OMT. Methylation (+ 14 Da) is  





This study presents the first characterisation of embedded OMT domains from 
trans-AT PKSs. A mass spectrometry based assay was designed and 
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implemented to assess the activity of these domains in vitro. The substrate 
tolerance of four embedded OMT domains from three different trans-AT PKSs 
was explored. This revealed the potentially useful substrate promiscuity of 
these domains. It was established that the embedded OMT domains showed 
regioselectivity for methylation of b-hydroxyl groups and it was found that three 
of the studied OMT domains were able to methylate hydroxyl groups of both 
stereochemistries. A completely conserved histidine residue was identified in 
OMT domains from trans-AT PKSs, and mutation of this residue to an alanine 
in the gladiolin OMT domain lead to the loss of activity. This suggests that this 
histidine is likely to act as the key catalytic base in these enzymes.   
 
OMT domains are always found after non-elongating (or hypothesised non-
elongating) KS domains in trans-AT PKSs. It was proposed that this was so 
that the KS domain could pass the growing polyketide chain to the downstream 
ACP domain, so that O-methylation could occur. Exploration of this, in the 
gladiolin O-methylation module, revealed that O-methylation was only able to 
occur on the downstream ACP domain, thus providing evidence for ACP 
domain specificity being the reason for the incorporation of non-elongating KS 
domains in O-methylation modules. Phylogenetic analysis of all known 
examples of embedded OMT domains from trans-AT PKSs revealed that 
these domains split into two distinct clades. OMT-ACP domain crosstalk 
assays revealed that the gladiolin OMT domain (clade II) was only able to 
methylate substrates when bound to ACP domains associated with other 
embedded OMT domains from the same clade. For the MisM1OMT domain 
(clade I) it was found that the OMT domain was able to methylate substrates 
bound to all ACP domains tested, however, a greater extent of methylation 
was observed for ACP domain associated with OMT domains from the same 
clade, suggesting that there is a stronger interaction between these domains. 
These results indicate that two different methods of communication may exist 
between embedded OMT domains and ACP domains, and that this is a 
contributing factor to the formation of the two clades.  
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Chapter 3 
 






In the gladiolin BGC there are several putative auxiliary genes of unknown 
function65. Two are of particular interest; gbnC that encodes for an asparagine 
synthetase homologue and gbnM which encodes for an amidase (Figure 3.1 
(A)). Asparagine synthetase enzymes catalyses the transfer of the amide 
nitrogen of glutamine to the side chain of aspartic acid in an ATP dependant 
reaction116, and amidase enzymes usually catalyse the hydrolysis of an amide, 
generating a carboxylic acid and ammonia117 (Figure 3.1 (B)). As the structure 
of gladiolin contains no nitrogen atoms this raises the question of what role 
these genes play in the biosynthesis. 
 
Based on the general activity of these enzymes it is proposed that gbnC acts 
upon the carboxylic acid moiety of gladiolin which is derived from the 
hypothesised starter unit, succinyl-CoA, and thus gbnM would then be 
responsible for converting the resultant amide derivative to the mature 
antibiotic. 




Figure 3.1: (A) The gladiolin biosynthetic gene cluster, the two genes of 
interest gbnC and gbnM are highlighted in purple. (B) The general activity of 
the proposed enzymes. 
  
The use of protecting groups in the biosynthesis of antibiotics is well 
precedented. A common self-resistance mechanism employed by antibiotic 
producers to avoid suicide is to either build the antibiotic as a pro-drug, or to 
enzymatically modify the antibiotic to generate an inactive form, which would 
then be converted to the active compound immediately prior to or after export 
from the cell118. An example of this can be found in the biosynthesis of 
oleandomycin, a polyketide macrolide antibiotic from Streptomyces 
antibioticus. The BGC was found to encode for a glycosyltransferase that was 
shown to glycosylate oleandomycin, resulting in an inactive derivative. The 
cluster also encoded for a glycosidase that was able of convert glycosylated 
oleandomycin to the mature antibiotic119. 
 
There have also been several reported examples where protecting groups 
have been utilised in the biosynthesis of polyketides where cyclisation of 
intermediates would lead to the facile formation of either 5- or 6-membered 
rings120,121 (Figure 3.2 (A)). The succinyl-intermediate proposed in the initiation 
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of gladiolin biosynthesis would be prone to this (Figure 3.2 (B)), thus efficiency 
of biosynthesis may be improved through the transformation of the carboxylate 
moiety, to a less nucleophilic amide (the pKa of succinic acid is 4.2 so at 




Figure 3.2: (A) Examples of protecting groups used in the biosynthesis of 
Desertomycin and Vicenistatin. In each case the intermediate shown in bold, 
unless protected (protecting group shown in purple), would be vulnerable to 
cyclisation forming a 5- or 6-memebered ring. (B) Schematic showing how 
the intermediate proposed in the initiation of gladiolin biosynthesis would be 
prone to cyclisation. 
 
The aim of this study is to ascertain the role of the amidase, gbnM, and to 
investigate at what point in the gladiolin biosynthesis the asparagine 
synthetase, gbnC, acts, in order to obtain an insight into the role these genes 
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3.2 Identification of BGCs containing homologs of GbnC and 
GbnM 
 
Using ClusterTools78 (discussed in section 2.3.1) the MIBiG repository79 was 
searched for known BGCs containing homologs of both GbnM and GbnC. 
Three additional BGCs were found and the secondary metabolites for the 
identified pathways are shown in Figure 3.3 (A). Two share significant 
similarities with gladiolin; both etnangien and sorangicin are biosynthesised by 
trans-AT PKSs that are predicted to utilise dicarboxylic acid starter units, and 
they both demonstrate antibiotic activity through inhibition of RNA 
polymerase48,122. The role of the asparagine synthetase and amidase has not 
been determined for either of these biosynthetic pathways, however it is 
presumed analogous to their role in the biosynthesis of gladiolin. The identified 
exception was the phosphonate natural product fosfazinomycin, although the 
biosynthesis is not fully understood it is believed that these genes, which 
demonstrate substantially less sequence identity to the other homologs 
(Figure 3.3 (B)), are involved in the formation of the hydrazine moiety123. 
 
Genome mining using identified antibiotic resistance genes is a technique that 
has been successfully used to find novel antibiotics that act upon a chosen 
target of interest124. In an attempt to identify cryptic clusters encoding for 
potential RNA polymerase inhibitors that share a similar scaffold to gladiolin, 
a database constructed of all representative and reference genomes from 
NCBI was searched using ClusterTools. The search looked for biosynthetic 
pathways that contained both a homolog of GbnM and GbnC as well as a PKS 
KS domain and trans-AT docking domain, however no novel BGCs could be 
found. 
 




Figure 3.3: (A) The structure of secondary metabolites produced by BGCs 
containing homologs of both GbnC and GbnM; the carboxylic acid moiety 
that these genes are proposed to act upon is highlighted in blue. (B) 
Percentage identity matrices showing the similarity between each gene and 
their identified homologs. 
 Investigating cryptic starter unit amidation 
 64 
3.3 Investigating the role of gbnM 
 
3.3.1 Creation of knock-out mutants in B. gladioli BCC1622 
 
In order to study the role of gbnM, and the other genes of interest, in vivo a 
mutagenesis system based on the homing endonuclease I-SceI, which had 
been optimised for use in Burkholderia species, was used125 (Figure 3.4).  
 
First the sequences flanking the gene targeted for deletion were cloned into 
the pGPI suicide plasmid. This plasmid was then transferred into the gladiolin 
producer, B. gladioli BCC1622, by triparental mating. This strain was chosen 
as the target for gene deletions as the original gladiolin producer, B. gladioli 
BCC0238, was not amenable to genetic manipulation due to a high level of 
antibiotic resistance. Trimethoprim selection was used to drive homologous 
recombination, as the pGPI plasmid is not able to self-replicate, so targeted 
insertion of the plasmid into the chromosome is necessary for survival. The 
pGPI vector contains an I-SceI recognition site, so upon introduction of the 
pDAI-SceI plasmid that constitutively expressed the I-SceI nuclease, again by 
triparental mating, a double stranded cut in the DNA was formed. This 
promoted intramolecular recombination that either introduced the desired 
mutation or re-formed the wild type (WT). 
 




Figure 3.4: Overview of the homing endonuclease I-SceI mutagenesis system 
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3.3.2 In vivo studies 
 
To ascertain the role of the amidase, gbnM, a mutant with the gene cleanly 
deleted was created using the method discussed in the previous section. PCR 





Figure 3.5: Agarose gel electrophoresis showing genetic evidence for the 
creation of a gbnM deletion mutant in B. gladioli BCC1622. 
 
The secondary metabolite profile of a successful mutant was analysed by 
high-resolution LC-MS (Figure 3.6). B.gladioli BCC1622DgbnM produced a 
compound with a reduced retention time and mass decrease of 1 Da 
compared to the WT which was consistent with what would be expected for a 
more polar amide derivative of gladiolin. To confirm that the introduced 
mutation was responsible for this observation, the mutant was complemented 
by in trans expression of gbnM, which resulted in partial restoration of gladiolin 
production. The complementation was achieved using the arabinose-inducible 
pMLBAD vector, which gbnM was cloned into. This vector was chosen as it 
had been shown to effectively express genes in Burkholderia cepacia126. This 
result establishes that amidation of gladiolin or a gladiolin precursor plays a 
role in the biosynthesis. 




Figure 3.6: Base peak chromatograms from LC-MS analyses of extracts from 
agar-grown cultures of B. gladioli BCC1622 WT (black), B. gladioli 
BCC1622DgbnM (purple) and B. gladioli BCC1622DgbnM following in trans 
expression of gbnM (blue). The gbnM deletion mutant produced an amide 
derivative of gladiolin for which the high-resolution MS data is shown, 
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3.3.3 Isolation and structure elucidation of amide gladiolin 
 
This work is in collaboration with Dr Yousef Dashti, University of Warwick, 
who assisted in performing and assigning the NMR of amide gladiolin and 
who also assigned the NMR of iso-amide gladiolin. 
 
 
To isolate amide gladiolin for characterisation, B. gladioli BCC1622DgbnM was 
grown on BSM agar (1 L) for 2.5 days. The crude ethyl acetate extract was 
purified by reverse-phase high-performance liquid chromatography (HPLC) 
yielding amide gladiolin (14 mg) as a white solid (Appendix 5). Gladiolin was 
also purified from a culture of B. gladioli BCC1622 WT, which was used for 
comparison during this study.  
 
High resolution MS analysis of amide gladiolin showed a peak corresponding 
to [M+H]+ at m/z = 778.5483 that was consistent with the predicted molecular 
formula C44H75NO10 (calculated mass for C44H76NO10+: 778.5464, Appendix 6). 
The NMR assignments for amide gladiolin were very similar to that reported 
for gladiolin65, with distinct differences seen only for chemical shifts related to 
the amide moiety and the adjacent methylene group (Table 3.1, the NMR 
spectra can be found in Appendix 7). The proton spectrum revealed two 
distinctive exchangeable amide protons at δH 6.65 and 7.22, and in the HMBC 
spectrum both of these protons showed 2JCH coupling to the carbon of the side 
chain carbonyl (δC 174.7). In addition, the proton at δH 6.65 showed 3JCH 
coupling to the carbon of the expected adjoining methylene group (δC 32.93), 
thus confirming that amidation occurs on the carboxylic acid moiety of gladiolin 
(Figure 3.7). Similarity of the rest of the chemical shift assignments to gladiolin 









Figure 3.7: Chemical structure of amide gladiolin showing the key HMBC and 
COSY correlation confirming the position of the amide moiety. 
 
Table 3.1: NMR assignments for amide gladiolin (DMSO-d6, 600 Hz) 
compared to those published for gladiolin65. * indicates that the signal was 
found under the DMSO-d6 peak, and ** that the signal was found under the 
water peak. Highlighted in blue are the chemical shift assignments that differ 
most significantly. Refer to figure 3.7 for the positions. Multiplicity is denoted 
as follows: s = singlet, d = doublet, dd = doublet of doublets, dt = doublet of 
triplets, br = broad, m = multiplet and ol = overlapped. 
 
 Amide gladiolin Gladiolin 
Position  dH (J, Hz) dC dH (J, Hz) dC 
1 - 171.3 - 170.9 
2 2.22, 2.40, 2 x 1H, 
2 x m 
39.6* 2.22, 2.40, 2 x 1H,  
2 x m 
39.6 
3 3.94, 1H, m 69.3 3.95, 1H, m 68.9 
3-OH 4.69, 1H, d, (5.6) - 4.05, ol - 
4 1.46, 1H, m 43.7 1.46, 1H, m 43.8 
4-Me 0.79, 3H, d, (6.4) 9.7 0.79, 3H, d, (6.5) 9.6 
5 3.72, 1H, m 69.1 3.71, 1H, m 68.8 
5-OH 4.35, 1H, ol - 4.02, ol - 
6 1.46, 2H, m, ol 39.2* 1.46, 2H, m 39.6 
7 3.54, 1H, m 70.7 3.54, 1H, m 70.6 
7-OH 4.36, 1H, ol - 4.02, 1H, br s - 
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8 1.62, 1H, m 36.5 1.62, 1H, m 37.0 
8-Me 0.79, 3H, d, (6.7) 13.6 0.78, 3H, d, (6.0) 13.3 
9 1.94, 2.18, 2 x 1H,  
2 x m 
35.9 1.92, 2.18, 2 x 1H,  
2 x m 
35.8 
10 5.71, 1H, dt,  
(6.6, 14.5) 
133.0 5.71, 1H, dt,  
(6.5, 15.0) 
133.0 
11 6.29, 1H, dd,  
(10.96, 15.00) 
126.5 6.29, 1H, dd,  
(11.0, 15.0) 
126.1 
12 6.01, 1H, ol 130.0 6.02, 1H, (11.0, 11.0) 129.7 
13 5.31, 1H, ol 125.4 5.31, 1H, dt,  
(7.0, 11.0) 
125.0 
14 2.26, 2.36, 2 x 1H,  
2 x m 
30.6 2.26, 2.38, 2 x 1H,  
2 x m 
30.0 
15 3.18, 1H, m 80.1 3.18, 1H, dd, (5.5, 5.5) 79.6 
15-OMe 3.23, 3H, s 55.8 3.23, 3H, s 55.5 
16 1.31, 1.46, 2 x 1H,  
2 x m 
33.2 1.32, 1.48, 2 x 1H,  
2 x m 
32.2 
17 1.21, 1.36, 2 x 1H,  
2 x m 
21.2 1.23, 1.36, 2 x 1H,  
2 x m 
21.1 
18 1.24, 1.28, 2 x 1H, 
m, ol 
38.3 1.32, 1.30, 2 x 1H,  
2 x m 
36.2 
19 3.38** 66.4 3.38, 1H, m 66.1 
19-OH 4.17, 1H, d, (5.9) - 3.54, 1H, ol - 
20 1.50, 2H, m 36.4 1.49, 1.61, 2 x 1H,  
2 x m 
36.3 
21 5.30, 1H, m, ol 72.0 5.30, 1H, m 71.8 
22 1.80, 1H, m 42.2 1.80, 1H, m 42.1 
22-Me 0.67, 3H, d, (7.03) 10.2 0.69, 3H, d, (6.5) 10.4 
23 3.99, 1H, m 68.1 3.98, 1H, m 67.8 
23-OH 4.66, 1H, d, (4.03) - 4.46, 1H, br s - 
24 5.06, 1H, d, (8.90) 127.9 5.06, 1H, d, (8.5) 127.6 
25 - 135.5 - 134.7 
25-Me 1.59, 3H, s 16.5 1.59, 3H, s 16.2 
26 2.02, 2H, ol 39.1* 2.02, 2H, m 38.9 
27 2.14, 2H, m 30.5 2.12, 2H, m 30.1 
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28 5.54, 1H, ol 131.6 5.54, 1H, dt,  
(7.0, 15.0) 
130.2 
29 5.98, 1H, m, ol 130.6 5.98, 1H, dd,  
(11.0, 15.0) 
131.1 
30 5.95, 1H, ol 131.7 5.96, 1H, dd,  
(11.0, 15.0) 
131.9 
31 5.57, 1H, ol 129.4 5.56, 1H, dt,  
(7.0, 15.0) 
129.2 
32 2.08, 2H, m 41.6 2.08, 2H, m 41.3 
33 3.99, 1H, m 67.6 3.49, 1H, m 67.1 
33-OH 4.37, 1H, ol - 3.80, 1H, br s - 
34 1.04, 1.28, 2 x 1H,  
2 x m 
44.0 1.04, 1.28, 2 x 1H,  
2 x m 
43.6 
35 1.61, 1H, m, ol 28.4 1.61, 1H, m 28.1 
35-Me 0.80, 3H, d, (6.3) 18.9 0.80, 3H, d, (6.5) 17.9 
36 2.02, 2H, m, ol 32.5 1.32, 1.47, 2 x 1H,  
2 x m 
32.3 
37 1.29, 1.46, 2 x 1H,  
2 x m 
32.9 2.14, 2.19, 2 x 1H,  
2 x m 
29.9 
38 - 174.7 - 174.9 
NH2 6.65, 7.22, 2 x 1H,  
2 x br s 
- - - 
 
3.3.4 Stability of amide gladiolin in protic solvents 
 
Gladiolin was found to undergo slow conversion to a 24-memebered lactone 
isomer in protic solvents such as methanol. This isomerisation occurred via 
the nucleophillic addition of the C-23 hydroxyl group to the ester bond followed 
by elimination of the C-21 hydroxyl group65 (Figure 3.8 (A)). This conversion 
was also seen for amide gladiolin, generating iso-amide gladiolin (Figure 3.8 
(A), characterisation of which can be found in Appendix 8). The rate of this 
conversion appeared to be faster for amide gladiolin (Figure 3.8 (B)); the 
reason for this is not apparent but it is possible that the presence of the amide 
moiety changes the conformation of the molecule in solution, bringing the C-
23 hydroxyl group closer to the ester bond. This indicates that amide 
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hydrolysis, catalysed by GbnM, is responsible for generating a comparatively 




Figure 3.8: (A) The conversion of amide gladiolin to iso-amide gladiolin. (B) 
Base peak chromatograms from the LC-MS time-course analysis showing the 
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3.3.5 In vitro studies 
 
To further verify the activity of GbnM, complementary in vitro studies were 
conducted. GbnM was cloned into the vector pET28a for protein expression, 
however the amidase was poorly overproduced in E. coli and was almost 
exclusively insoluble. Secondary structure prediction by Phyre2 89 suggested 
that the amidase may contain a trans-membrane helical domain which could 
explain the difficulty in overproducing soluble protein (the same prediction was 
also made for the homologues from etnangien and sorangicin biosynthesis); 
membrane association would not be unexpected should this protein play a role 
in self-protection. In an attempt to overcome this buffers containing the 
detergent Triton X-100 or CHAPS were trialled during protein extraction, as 
detergents have often proved useful in the solubilisation of membrane 
associated proteins127, however this was not successful. For this reason the 
assay was conducted using cell lysate. The presence of GbnM in the cell 
lysate was confirmed by SDS-PAGE analysis (Figure 3.9 (B)). 
 
In vitro activity of GbnM was demonstrated by incubating purified amide 
gladiolin (see section 3.3.3 for details on the purification) with cell lysate 
containing overproduced GbnM (Figure 3.9 (A)). As expected, LC-MS analysis 
revealed the appearance of a product peak with an identical mass and 
retention time to the gladiolin standard (Figure 3.9 (C)). In order to ensure that 
the observed activity was not the result of any other proteins present in the cell 
lysate a control experiment was conducted using cell lysate from E. coli BL21 
containing the empty pET28a vector. Conversion to gladiolin was not detected, 
thus verifying that GbnM was responsible for the observed conversion. 
 




Figure 3.9: (A) Overview of the assay used to demonstrate activity of GbnM 
in vitro. (B) 10 % SDS-PAGE analysis showing the presence of GbnM in the 
cell lysate. (C) Base peak chromatograms from LC-MS analysis of the assay 
showing the conversion of amide gladiolin to gladiolin by GbnM, the peaks 
marked with * result from isomerisation. 
 
3.4 Antimicrobial activity of amide gladiolin 
 
Purified amide gladiolin was tested for its antimicrobial activity against a range 
of clinically relevant pathogens, which included representative members of the 
ESKAPE panel. The ESKAPE panel consists of bacteria that demonstrate 
concerning levels of antibiotic resistance128. The minimum inhibitory 
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concentrations (MICs) were determined using the broth microdilution method 
(Table 3.2).  
 
Table 3.2: MIC values determined for amide gladiolin against C. albicans and 
a range of gram-negative and gram-positive bacteria. The MIC values 










Klebsiella pneumonia DSM26371 >64 >64 
Acinetobacter baumannii DSM25645 8 32 
Pseudomonas aeruginosa DSM29239 64 >64 
Enterobacter cloacae DSM16690 64 >64 
Escherichia coli SY327 16 >64 
Burkholderia gladioli BCC1622 >64 >64 
Gram-positive bacteria 
  
Enterococcus faecium DSM25390 2 2 
Staphylococcus aureus DSM21979 4 8 
Fungi 
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The MIC assays revealed that amide gladiolin was moderately active against 
gram-positive bacteria and C. albicans. Interestingly, amide gladiolin, unlike 
gladiolin, demonstrated moderate antimicrobial activity against gram-negative 
bacteria, including A. baumannii and E. coli. This suggests that amidation of 
gladiolin improved the permeative ability of the antibiotic to the often 
impenetrable outer membrane of these bacteria. Amide gladiolin was also 
tested against B. gladioli BCC1622, the producer of the gladiolins, in an 
attempt to see if it displayed resistance, however no activity was observed for 
either amide gladiolin or gladiolin. Presumably, the outer membrane in B. 
gladioli acts as a barrier to the influx of the antibiotics.  
 
As gladiolin demonstrated potent antimicrobial activity against M. 
tuberculosis65, and the structurally related etnangien was found to be active 
against a range of other Mycobacterium species including M. smegmatis66, it 
was thus decided to evaluate the in-vitro activity of amide gladiolin against M. 
smegmatis. M. smegmatis is often used as an in vitro model for determining if 
a compound is likely to demonstrate activity towards M. tuberculosis owing to 
its much shorter generation time and the fact that it is considered to be non-
pathogenic129. The resazurin microtiter assay was used, which is a simple and 
inexpensive technique for determining the MICs of Mycobacteria using the cell 
permeable redox indicator resazurin. Viable cells with an active metabolism 
will reduce rezasurin, which is blue, to resorufin, which is pink (Figure 3.10)130. 
The MIC was defined as the lowest antibiotic concentration that prevented the 
colour change from blue to pink. It was found that amide gladiolin was slightly 
more active than gladiolin against M. smegmatis, 16 µg/mL compared to 32 
µg/mL respectively (Table 3.3). It was thus tested for activity against M. 
tuberculosis, which was conducted by the Fullam Lab (School of Life 
Sciences, University of Warwick) as part of a TB screening initiative funded by 
INTERGRATE EPSRC (grant number EP/M027503/1). The MIC for M. 
tuberculosis H37Rv was determined to be 2 µg/mL. 




Figure 3.10: The rezasurin microtiter assay used to determine the MIC of 
amide gladiolin and gladiolin for M. smegmatis. 
 
Table 3.3: MIC values determined for amide gladiolin against M. smegmatis 
and M. tuberculosis. The value shown in blue is the value reported by Song 








Mycobacterium smegmatis DSM43756 16 32 
Mycobacterium tuberculosis H37Rv 2 0.465 
 
The antimicrobial activity of amide gladiolin suggests that this antibiotic is still 
capable of efficiently inhibiting RNA polymerase, although this will need to be 
experimentally investigated to confirm the target for the compound was not 
affected by the amidation. It was reported that for sorangicin, this was not the 
case as a chemically synthesised amide derivative maintained the ability to 
inhibit E. coli RNA polymerase131. This suggests that amidation alone is not 
able to confer resistance. Interestingly, a crystal structure of Thermus 
 Investigating cryptic starter unit amidation 
 78 
aquaticus RNA polymerase in complex with sorangicin revealed that the side 
chain was not involved in RNA polymerase interactions and that the carbonyl 
of the carboxylic acid moiety only formed a hydrogen bond with the macrolide 
core, possibly to maintain a certain molecular conformation, which an amide 
would also be capable of (Figure 3.11)1. This calls into question how the RNA 
polymerase of a producing organism could possess an adaption that provided 
resistance to the amide derivative and not the mature antibiotic, and thus 





Figure 3.11: Image of sorangicin (purple) in complex with Thermus aquaticus 
RNA polymerase (PDB: 1YNJ1). Hydrogen bonds are shown with dashed 
lines with those to the protein shown in blue, and the intramolecular hydrogen 
bond between the carboxylic acid moiety and the macrolide core shown in 
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3.5 Investigating the action of gbnC 
 
3.5.1 In vivo studies 
 
To investigate the role of the asparagine synthetase, gbnC, in the biosynthesis 
of gladiolin the gene was inactivated through the creation of an in-frame 
deletion using the method discussed in section 3.3.1, and a successful mutant 
was identified by PCR analysis (Figure 3.12). High-resolution LC-MS analysis 
of the extract of an agar culture of B. gladioli BCC1622DgbnC revealed that 
production of gladiolin was completely abolished (Figure 3.13). The deletion 
mutant was complemented by in trans expression of gbnC which restored 
gladiolin production to a limited extent.  A better level of complementation 
could not be achieved even with increasing the concentration of arabinose, 
which induces expression, in the media (Figure 3.13 (B)). This could be due 
to the fact that arabinose offers the bacteria an alternative carbon source, 
leading to a shift in the secondary metabolite profile, which could disfavoured 
gladiolin production. This result established that gbnC, plays an essential role 




Figure 3.12: Agarose gel electrophoresis showing genetic evidence for the 
creation of a gbnC deletion mutant in B. gladioli BCC1622. 




Figure 3.13: (A) Base peak chromatograms from LC-MS analyses of extracts 
from agar-grown cultures of B. gladioli BCC1622 WT (black), B. gladioli 
BCC1622DgbnC (purple) and B. gladioli BCC1622DgbnC following in trans 
expression of GbnC (blue). The extracted ion chromatogram for the [M+Na]+ 
ion is also shown. (B) Base peak chromatograms from LC-MS analyses  of 
extracts from cultures of B. gladioli BCC1622DgbnC where the media was 
supplemented with increasing concentrations of arabinose (blue). For 
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3.5.2 Complementation with the homolog SorQ  
 
Attempts to overproduce the asparagine synthetase, GbnC, as a 
hexahistidine-tagged recombinant protein were unsuccessful; the resultant 
protein was completely insoluble, and the solubility of the protein could not be 
improved, even with the inclusion of the small ubiquitin-like modifier (SUMO) 
or maltose-binding protein (MBP) solubility tag, which have been reported to 
enhance the overproduction, stability and solubility of numerous proteins132. 
The same insolubility was also found for SorQ, a homologue of GbnC, from 
the sorangicin biosynthetic pathway, that shares 50% amino acid sequence 
identity (Figure 3.3 (B)). 
 
As in vitro studies with GbnC were not possible, complementation of B. gladioli 
BCC1622DgbnC by in trans expression of sorQ was attempted. The structure 
of sorangicin and gladiolin are largely different but intermediates in polyketide 
chain initiation are likely to be similar. The gladiolin starter unit is proposed to 
be succinyl-CoA and for sorangicin it is hypothesised to be malonyl-CoA. If 
complementation could be achieved this would suggest that the asparagine 
synthetase is likely to act pre-polyketide assembly. Unfortunately, 
complementation was not observed (Figure 3.14). The reason for this could 
be that B. gladioli was unable to produce SorQ as a functional and soluble 
protein given that its origin is from a very different organism, or that succinyl-
CoA, ACP bound succinyl derivatives or gladiolin were not substrates for this 
protein. 
 




Figure 3.14: Base peak chromatograms from LC-MS analyses of extracts from 
agar-grown cultures of B. gladioli BCC1622 WT (black), B. gladioli 
BCC1622DgbnC (purple) and B. gladioli BCC1622DgbnC following in trans 
expression of sorQ (blue). The extracted ion chromatogram for the [M+Na]+ 
ion is also shown. 
 
 
3.6 Exploration of polyketide chain initiation in the 
biosynthesis of gladiolin 
 
3.6.1 Proposed mechanisms of chain initiation 
 
As the action of the asparagine synthetase, GbnC, could not be investigated 
directly the cryptic initiation of gladiolin biosynthesis was studied, in hope of 
revealing whether amidation is necessary for initiation of polyketide 
biosynthesis. The gladiolin PKS lacks a conventional clearly demarcated 
loading module, however, there is a standalone ACP domain, GbnA, that has 
yet to be accounted for in the biosynthesis of gladiolin, which could act as the 
loading module. The gladiolin BCG cluster was also found to encode for an 
AT-like enzyme, GbnB, which clades independently to malonyl-CoA specific 
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AT domains (Appendix 9). As KirCII, from the kirromycin pathway, which 
demonstrates selectivity for ethyl-malonyl-CoA in vitro47 and OzmC, from the 
oxazolomycin pathway, that is proposed to utilise methoxymalonyl-CoA49, also 
clade separately, it is proposed that GbnB will show selectivity towards the 
starter unit, succinyl-CoA. Homologs of both GbnA and GbnB can be found in 
the etnangien BGC. It is therefore hypothesised that GbnB loads succinyl-CoA 
onto the ACP domain, GbnA, and the succinyl moiety is subsequently 
transferred from GbnA to the KS domain of GbnD1, from which polyketide 
chain assembly can proceed (Figure 3.16 (A)). A similar mechanism to this is 
proposed for the chain initiation in the biosynthesis of the glutarimide-
containing polyketides (Figure 3.15)50. Amidation (also of a terminal 
carboxylate moiety) must play a role at some stage during early biosynthesis, 
as the domains that have been shown to install the glutarimide moiety can 
always be found in the second non-elongating part of module 1 of the 






Figure 3.15: Proposed chain initiation mechanism in the biosynthesis of the 
glutarimide-containing polyketides. AS = asparagine synthetase homolog. 
This proposed initiation mechanism can be found in the lactimidomycin (Ltm) 
PKS135, cycloheximide (Chx) PKS136, iso-migrastatin (Mgs) PKS134 and the 9-
methyl-streptimidone (Smd) PKS137. 
 




Figure 3.16: Proposed alternative mechanisms of polyketide chain initiation 
in the biosynthesis of gladiolin. Potential substrates for the asparagine 
synthetase (GbnC) are shown in purple. In mechanism (A) the AT domain 
(GbnB) loads succinyl-CoA onto the standalone ACP domain (GbnA), prior to 
the succinyl moiety being transferred to the KS domain of GbnD1. In 
mechanism (B) GbnB loads succinyl-CoA directly onto the first ACP domain 
of GbnD1 and the starter unit is then back transferred onto the KS domain so 
that chain elongation can occur. In mechanism (C) the first KS domain of 
GbnD1 directly accepts succinyl-CoA as a substrate.  
 
It is also, however possible that succinyl-CoA is directly loaded onto the first 
ACP domain of GbnD1 by GbnB, and subsequently back transferred onto the 
active site of the KS domain so that chain elongation can occur (Figure 3.16 
(B)), or that neither of these enzymes are required and the KS domain of 
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GbnD1 can directly accept succinyl-CoA (Figure 3.16 (C)). Self-loading of the 
starter unit onto the first KS domain has been demonstrated for the 
erythromycin pathway, where deletion of the loading module did not terminate 
biosynthesis, although a notable drop in the biosynthetic efficiency was 
observed138. 
 
Should amidation of the carboxylic acid moiety act as a biosynthetic protecting 
group it would be anticipated that the asparagine synthetase, GbnC, would act 
either upon Succinyl-CoA, creating a pool of substrate for the PKS, or on the 
ACP bound succinyl moiety which would be vulnerable to cyclisation (Figure 
3.2 (B)). 
 
3.6.2 Establishing the importance of gbnA and gbnB in the 
biosynthesis of gladiolin 
 
To confirm the involvement of the ACP domain (GbnA) and the AT domain 
(GbnB) in the biosynthesis of gladiolin, gene deletion mutants were created 
using the method discussed in section 3.3.1. Mutants with the correct 
genotype were identified by PCR analysis (Figure 3.17 (A)). Both of these 
mutants lost the ability to produce gladiolin, indicating that both GbnA and 
GbnB play an essential role in the biosynthesis (Figure 3.17 (B)). To fully 
confirm this complementation by in trans expression of the deleted genes is 
ongoing. 
 




Figure 3.17: (A) Agarose gel electrophoresis showing genetic evidence for 
the creation of a gbnA and gbnB deletion mutant in B. gladioli BCC1622. (B) 
Base peak chromatograms from LC-MS analyses of extracts from agar-grown 
cultures of B. gladioli BCC1622 WT (black), and the generated mutants 
(purple). In both deletion mutants the production of gladiolin was abolished. 
 
3.6.3 Overproduction and purification of proteins involved in chain 
initiation 
 
In order to test the hypothesised mechanism for chain initiation in vitro, GbnA, 
GbnB, and the first ACP domain from the gladiolin biosynthetic pathway, 
GldM1ACP(I), were heterologously overproduced as hexa-histidine tagged 
proteins, which were purified by nickel-NTA chromatography. This was 
achieved by cloning the gene, or section of DNA, of interest into the expression 
vector pET28a as discussed in section 2.4.1. The malonyl-specific AT domain, 
EtnK, was also overproduced and purified, from a synthetic pET24a construct. 
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This was used for comparison with GbnB as the malonyl-specific AT domain 
for the gladiolin pathway, GbnN, did not give soluble protein when 
overproduced in E. coli. A second malonyl-specific AT domain was also used 
for comparison, PksC from the bacillaene biosynthetic pathway (the purified 
protein was kindly provided by Dr Matthew Jenner). This was used as the 
bacillaene pathway does not utilise succinyl-CoA at any stage during 
biosynthesis53. SDS-PAGE analysis showed that the proteins were of a 
reasonable level of purity and of the expected molecular weight (Figure 3.18), 
which was confirmed by intact protein MS (Appendix 1).  
 
An attempt was made to obtain the first KS domain from the gladiolin PKS, 
GldM1KS, as a purified protein, however overproduction yielded only insoluble 
protein. It is possible that the protein was insoluble due to disruption of the 
secondary structure. The chosen domain boundaries were based on 
predictions made by antiSMASH 2.0, and it is hoped that through trialling 






Figure 3.18: (A) 12 % SDS-PAGE analysis of the purified AT domains GbnB 
and EtnK. (B) 15 % SDS-PAGE analysis of the purified ACP domains GbnA 
and GldM1ACP(I). 
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3.6.4 Investigating the substrate tolerance of GbnB 
 
The activity of the AT domain, GbnB, was tested by incubating it with succinyl-
CoA. For comparison, the same assay was performed with the proposed 
malonyl-specific AT domains, EtnK and PksC, from the etnangien48 and 
bacillaene biosynthetic pathway53, respectively. Intact protein MS was used to 
analyse whether the succinyl-moiety could be loaded onto the active site 
serine residue of the AT domains. Interestingly, it was found that all three of 
the AT domains were able to accept succinyl-CoA, determined by an observed 
mass increase of 100 Da, although complete loading was observed only for 
GbnB (Figure 3.19). Malonyl-CoA was also tested as a potential substrate for 
GbnB, and complete loading of all three of the AT domains was observed. 
 
The ability of GbnB to accept succinamic-CoA was next investigated. As 
succinamic-CoA was not commercially available and would be challenging to 
synthesise, a biosynthetic approach was chosen that utilised the class III CoA 
transferase, VbxP, from the vibroxin biosynthetic pathway, which was found to 
be capable of generating a wide scope of CoA analogues from the 
corresponding acids and acetyl-CoA (purified VbxP was kindly provided by 
Christian Hobson)139. Overnight incubation of an (5X) excess of succinamic 
acid with VbxP and acetyl-CoA lead to the complete conversion of acetyl-CoA 
to succinamic-CoA (Figure 3.20). VbxP was removed from the reaction 
mixture using a 5 kDa MWCO spin filter and the resultant flow through was 
incubated with GbnB. It was discovered that succinamic-CoA was not a 
substrate for this AT domain, and as expect it was also not accepted by the 
malonyl-specific AT domains (Figure 3.19). 




Figure 3.19: Stacked deconvoluted ESI-MS spectra of the AT domains GbnB, 
EtnK and PksC showing whether they are capable of accepting succinyl-CoA 
(first), malonyl-CoA (middle) or succinamic-CoA (last) as substrates. 
Succinamic-CoA was not a substrate for any of the AT domains. For the 
control reactions the CoA derivatives were omitted (for succinamic-CoA the 
VbxP control reaction was used for the control to demonstrate that free 
succinamic acid could not self-load onto the AT domains).   




Figure 3.20: (A) Overview of the VbxP catalysed reaction used to generate 
succinamic-CoA. (B) Base peak chromatograms from the LC-MS analysis of 
the CoA transferase, VbxP, catalysed reaction of acetyl-CoA with succinamic 
acid (purple) and the control reaction using boiled VbxP (black). VbxP was 
able to completely convert acetyl-CoA to succinamic-CoA for which the high-
resolution MS data is shown, alongside the MS data of acetyl-CoA for 
comparison. 
 
As succinyl-CoA was found to be a substrate for GbnB, the next step will be 
to determine if GbnB is capable of transferring the succinyl unit onto the 
phosphopantetheinyl moiety of either holo-GbnA or holo-GldM1ACP(I). This 











In this study, the gene, gbnM, that encodes for a putative amidase, which was 
unaccounted for in the gladiolin biosynthetic pathway, was cleanly deleted 
generating a mutant strain B. gladioli BCC1622DgbnM that produced a novel, 
amidated analogue of gladiolin. This revealed that amidation of gladiolin or a 
gladiolin precursor plays a role in the biosynthesis. Characterisation of amide 
gladiolin revealed that amidation, which was shown to occur on the carboxylic 
acid moiety of gladiolin, did not result in the loss of antimicrobial activity. In fact 
amide gladiolin was found to display moderate antimicrobial activity against 
the gram-negative bacteria, A. baumanni and E. coli, which was not seen for 
gladiolin. The fact that amide gladiolin maintained a similar level of 
antimicrobial activity to gladiolin suggests that amidation may not play a 
primary role in self-resistance, as was initially hypothesised. 
 
Studies on the complementary gene, gbnC, which encodes for a putative 
asparagine synthetase, that is proposed to amidate the carboxylic acid moiety, 
proved to be not straightforward. Inactivation of gbnC in vivo abolished 
production of gladiolin, which established that GbnC plays an essential role in 
the biosynthesis. Unfortunately, in vitro studies were not possible due to GbnC 
being completely insoluble when recombinantly overproduced in E. coli. To 
ascertain whether GbnC acts prior to polyketide assembly, investigation into 
the cryptic chain initiation in gladiolin biosynthesis was begun. It was 
established that the unusual AT domain was able to accept the proposed 
starter unit, succinyl-CoA, however, it will need to be determined if this AT 
domain is capable of loading the succinyl-unit onto either of the ACP domains 
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Chapter 4 
 
Conclusions and perspectives  
 
 
4.1 O-methylation during chain assembly by trans-AT 
modular polyketide synthases 
 
This study presents the first biochemical characterisation of embedded OMT 
domains from trans-AT PKSs. Embedded OMT domains could provide a novel 
approach to engineering methylation, where the position of methylation would 
depend only upon the location of the domain within the PKS. For successful 
bioengineering a comprehensive understanding of the biochemical activity and 
structure of the domain, as well as knowledge of the domain interactions is 
required.  
 
4.1.1 Exploration of the substrate tolerance of embedded OMT 
domains 
 
In order to assess the activity of embedded OMT domains in vitro a mass 
spectrometry based assay was designed and implemented. The substrate 
tolerance of four embedded OMT domains from three different polyketide 
assembly lines was explored, revealing potentially useful substrate 
promiscuity. It was found that each OMT domain showed its own unique 
substrate tolerance profile, however all of the OMT domains were found to 
accept at least some of the short substrate mimics used in this study, despite 
the proposed in vitro substrates being substantially longer. Three of the OMT 
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domains were able to methylate b-hydroxyl groups of both stereochemistries. 
This is likely due to the fact that there would be no evolutionary pressure on 
the OMT domains to demonstrate stereoselectivity, as the KR domains found 
within each methylation module would generate the hydroxyl group to be 
methylated in a stereospecific manner. It is probable that substituents 
surrounding the methylating hydroxyl groups will have the biggest influence 
over whether the substrate will be accepted by the OMT domain. It was 
demonstrated that three of the OMT domains were able to accept substrates 
that also had a  d-hydroxyl group. In growing polyketide chains substituents, 
most commonly methyl groups, can often be found in the a- and g- positions. 
Future work could, therefore, involve synthesising short pantetheine substrate 
mimics that possess a b-hydroxyl group as well as an a- or g- methyl group, 
and assessing their ability to be methylated by the OMT domains (Figure 4.1). 
Comprehensive knowledge of the substrate tolerance of embedded OMT 
domains will allow for an understanding of where these domains can be placed 




Figure 4.1: Proposed substrates for further exploring the substrate tolerance 
of embedded OMT domains from trans-AT PKSs. 
 
4.1.2 Characterising the interactions between embedded OMT 
domains and ACP domains 
 
Within O-methylation modules in trans-AT PKSs there is always a non-
elongating (or hypothesised non-elongating) KS domain found before the OMT 
domain, which is proposed to just translocate the polyketide chain to the 
downstream ACP domain so that O-methylation can occur. For the gladiolin 
O-methylation module the transacylation activity of the hypothesised non-
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elongating KS domain was proven. It was also demonstrated that methylation 
was only able to occur on the second ACP domain, thus establishing that a 
specific interaction is required between the OMT domain and ACP domain for 
catalytic activity. The fact that O-methylation could only be observed for the 
downstream ACP domain provides evidence towards ACP domain specificity 
being the reason for the incorporation of a non-elongating KS domains as part 
of the methylation module. 
 
Phylogenetic analysis revealed that embedded OMT domains from trans-AT 
PKSs formed two clades. OMT-ACP domain crosstalk assays revealed that 
the gladiolin OMT domain, from clade II, was only able to catalyse O-
methylation of substrates bound to ACP domains that were associated with 
other clade II OMT domains. Conversely, methylation was observed for the 
MisM1OMT domain, from clade I, when incubated with ACP domains 
associated with OMT domains from both clades, however, a greater extent of 
methylation was observed for ACP domains affiliated with other clade I OMT 
domains. This suggests that there are more significant OMT-ACP domain 
interaction between the domains associated with the same clade, and 
indicates that two different OMT-ACP domain communication mechanisms 
may have evolved.  
 
Future work could involve characterisation of these interactions. There are a 
number of techniques available for quantifying protein-protein interaction; one 
of the most commonly used techniques to determine binding affinities and 
association/dissociation kinetics is surface plasmon resonance. This involves 
immobilisation of one of the interacting proteins on a dedicated sensor surface, 
prior to the partner protein being injected across the surface of the immobilised 
protein. The binding is monitored by changes in the refractive index of the 
medium close to the surface, upon addition of the second protein140. It would 
also be interesting to map the binding sites for the OMT-ACP domain 
interactions to establish how they differ from each other, and from the 
interactions between ACP domains and other tailoring domains. This could be 
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achieved by carbene footprinting, which utilises diazirine reagents to carbene-
label the surface of proteins upon photoirradiation; the labelled residues are 
identified by MS analysis of the digested protein141. Binding sites are 
determined by comparing the labelling of a protein in the presence and 
absence of the interacting partner protein. To gain the most from this, however, 
a structure of an embedded OMT domain would be required.  
 
4.1.3 Structural studies of embedded OMT domains 
 
This work is in collaboration with Dr Hussain Buhkya, Monash University, 
who conducted and analysed the negative stain TEM imaging of GldM11KS-
OMT-ACP. 
 
Unfortunately, a crystal structure of the embedded OMT domain from the 
gladiolin biosynthetic pathway could not be obtained, as no conditions were 
identified that produced protein crystals. Inherent biochemical features of the 
protein can influence whether or not a protein is able to crystallise142, thus 
future work could involve setting up crystallisation trials for the other 
embedded OMT domains looked at in the study.  
 
Cryo-EM is an alternative structural biology technique that is able to determine 
high resolution (3-5 Å) structures of protein complexes that are 200 kDa or 
larger143, which has recently been applied to the study of the structure of a 
PKS module144. As cryo-EM is also able to provide information about the 
spatial organisation of domains and identify interaction surfaces between the 
proteins, it was decided that this would be a useful technique to apply to the 
KS(0)-OMT-ACP subset of domains, that were determined to be essential for 
O-methylation on trans-AT PKS assembly lines. GldM11KS-OMT-ACP was 
cloned into pET28a, and it was demonstrated that the tri-domain could be 
overproduced and purified to a high level of homogeneity, which was 
characterised by SDS-PAGE analysis and intact protein MS (Figure 4.2 (A), 
Appendix 1). The construct was subsequently provided to Dr Hussain Buhkya 
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(Challis group, Monash University), who is attempting to obtain high resolution 
cryo-EM images of this protein. Initial negative stain TEM data revealed that 
the protein (which was found to be around 14-17 nm in size, with the KS 
domain being approximately 6-7 nm and the OMT domain 8-9 nm) is suitable 
for cryo-EM studies, with a number of different orientations of the molecule 




Figure 4.2: (A) 8 % SDS-PAGE gel showing purified GldM11KS-OMT-ACP. 
(B) 2D class averages of the negative stain TEM images of the tri-domain 
protein obtained by classification of different conformations using EMAN 
2.1145. 
 
4.1.4 Bioengineering O-methylation 
 
The understanding of O-methylation on trans-AT PKS assembly lines gained 
from this study will hopefully provide a basis for future efforts towards rational 
engineering of O-methylation in these systems. The biosynthesis of gladiolin 
presents an application for this. Gladiolin (and amide gladiolin) undergoes 
conversion to a 24-membered lactone isomer in protic solvents due to 
nucleophillic addition of the C-23 hydroxyl group to the ester, followed by 
elimination of the C-21 hydroxyl group (Figure 3.9 (A)). Future work could 
involve attempting selective methylation of the C-23 hydroxyl group, to 
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increase the stability of gladiolin, via the introduction of the subset of domains 




Figure 4.3: Proposed bioengineering of the gladiolin PKS to introduce 
methylation of the hydroxyl-group at position 23. 
 
4.2 Investigating cryptic starter unit amidation 
 
4.2.1 Amide gladiolin 
 
In vivo inactivation of the putative amidase encoding gene, gbnM, from the 
gladiolin BGC lead to the discovery of a novel amide derivative of the antibiotic, 
and also provided evidence that GbnM is responsible for converting it to the 
mature antibiotic.  The ability of GbnM to hydrolyse the amide was confirmed 
by in vitro studies. The knowledge that amidation of gladiolin or a gladiolin 
precursor plays a role in the biosynthesis will prove useful for future 
biosynthetic studies, on this and similar PKS systems, as amidated 
biosynthetic intermediates may be required or observed. 
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The antimicrobial activity of amide gladiolin was determined for representative 
members of the ESKAPE panel as well as C. albicans and M. tuberculosis. It 
was found that the amidation of gladiolin did not result in the loss of 
antimicrobial activity and interestingly, lead to moderate activity against the 
gram-negative bacteria, A. baumannii and E. coli, that was not seen for 
gladiolin. Multidrug-resistant strains of A. baumannii, E. coli, and M. 
tuberculosis (for which the MIC of amide gladiolin was determined to be 2 
µg/mL) are of increasing clinical prevalence, so there is a pressing need for 
new antibiotics to treat such infections. Amide gladiolin could provide the basis 
for the development of an antibiotic to address this problem.  
 
4.2.2 The role of GbnC in the biosynthesis of gladiolin 
 
In vivo deletion of the putative asparagine synthetase encoding gene, gbnC, 
which is proposed to be responsible for the amidation of the carboxylic acid 
moiety of gladiolin, abolished the production of gladiolin and related 
metabolites. This established that gbnC plays an essential role in the 
biosynthesis. Unfortunately, in vitro studies to assess the activity of GbnC 
were not possible, as GbnC was completely insoluble when heterologously 
overproduced in E. coli. Bioinformatics revealed that the BGCs responsible for 
the biosynthesis of etnangien and sorangicin, both of which share numerous 
similarities to gladiolin, contain homologs of both GbnM and GbnC. It was 
established that SorQ, the homolog of GbnC from the sorangicin biosynthetic 
pathway was also completely insoluble when heterologously overproduced in 
E. coli. Future work could involve determining if soluble protein can be 
obtained from the overproduction of the homolog, EtnC, from the etnangien 
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4.2.3 Exploration of polyketide chain initiation in gladiolin 
biosynthesis 
 
To determine if amidation is necessary for initiation of polyketide biosynthesis, 
the cryptic chain initiation mechanism for gladiolin biosynthesis was 
investigated. The gladiolin PKS lacks a clearly demarcated loading module, 
however, there is a standalone ACP domain, GbnA, which was determined by 
in vivo inactivation to be essential for biosynthesis, that could act as the 
loading module. Polyketide chain initiation by a standalone ACP domain has 
been suggested to occur in a number of trans-AT PKSs50. 
 
The gladiolin BGC also encoded for a putative AT domain, GbnB, which was 
found to clade independently from malonyl-specific AT domains, thus it was 
proposed that this AT domain could be responsible for the loading of a 
succinyl-CoA starter unit. To investigate this, the substrate tolerance of GbnB 
was explored, and it was found that both succinyl- and malonyl-CoA were 
accepted substrates, but succinamic-CoA was not. If it can be confirmed that 
GbnB is responsible for the loading of the starter unit, then this will establish 
that GbnC does not act directly upon succinyl-CoA. Future work will involve 
determining if GbnB is able to transfer the succinyl-unit to GbnA, or the first 
ACP domain of GbnD1, and whether any selectivity is displayed. 
 
KS domains from trans-AT PKSs are known to play a gatekeeping role, by 
demonstrating specificity for the downstream polyketide intermediate146. This 
means that determining the substrate specificity of the N-terminal KS domain 
of GbnD1 will be key to proving if amidation is important for polyketide chain 
initiation. Unfortunately, initial attempts to overproduce this KS domain yielded 
only insoluble protein. Future work will involve testing a number of different 
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4.2.4 Revised gladiolin biosynthesis 
 
This research has revealed that the previously overlooked genes in the 
gladiolin BGC encoding for an asparagine synthetase (GbnC), an amidase 
(GbnM) and a standalone ACP domain (GbnA) play an essential role in the 
biosynthesis of gladiolin. It was initially hypothesised that the asparagine 
synthetase and amidase could play a role in antimicrobial self-resistance, 
however the observed antimicrobial activity of amide gladiolin suggests that 
amidation alone is not able to confer resistance. To ensure that amidation of 
gladiolin did not change the target of the antibiotic, a collaboration has been 
established with the Ebright Lab (Waksman Institute of Microbiology, Rutgers), 
who are looking to confirm that amide gladiolin acts by inhibition of RNA 
polymerase, and to also biochemically analyse the binding site and 
mechanism of the gladiolins. It is therefore probable that amidation of gladiolin 
acts as a biosynthetic protecting group. It is thus proposed that the 
biosynthesis of gladiolin proceeds in a similar fashion to the biosynthesis of 
the glutarimide-containing polyketides (Figure 3.15). The  starter unit succinyl-
CoA is first loaded onto the ACP domain GbnA, most likely by the AT domain 
GbnB, before being amidated by the asparagine synthetase, GbnC. The 
succinamic moiety is then passed onto the KS domain of GbnD1 and gladiolin 
is built as the amidated derivative. It was demonstrated, both in vivo and in 
vitro, that the amidase, GbnM, is able to convert amide gladiolin to the mature 
antibiotic. The revised biosynthesis of gladiolin is shown in Figure 4.4. 
 
As the BGCs of both etnangien and sorangicin contain homologs of the 
asparagine synthetase and amidase, and the biosynthesis of these 
polyketides also utilise a dicarboxylic acid starter unit it is very likely that these 
biosynthesises proceed in the same way as proposed for the biosynthesis of 
gladiolin. The sorangicin BGC is missing a homolog of the standalone ACP 
domain (GbnA), however it is suggested that the sorangicin BGC has a split 
cluster organisation as the b-branching cassette required for the biosynthesis 
of sorangicin is absent from the identified BGC147. 




Figure 4.4: Revised pathway for gladiolin biosynthesis, showing the ACP-
bound predicted polyketide intermediates following a- and b-carbon 
processing. Black circles represent ACP domains. The domain with a cross 
through it indicates that the domain lacks the key catalytic residues required 
for activity. AS= asparagine synthetase and AM= amidase. 
 






5.1 Microbial strains and culture conditions 
 
5.1.1 Microbial strains 
 
Table 5.1: Bacterial and fungal strains used within this project. Strains shown 
in dark blue are risk group 2 microorganisms. 
Microbial strain Growth 
temperature 
Use Source  
Escherichia coli    
TOP10  
(chemically competent) 










37 °C Cloning, plasmid 
propagation and donor 
strain for conjugation 
between E. coli and B. 
gladioli 
Lab stock 
HB101 (pRK 2013) 37 °C Helper strain for 
conjugation between 















Other    
Burkholderia gladioli 
BCC1622 
30 °C Genetic manipulation 











































































Candida albicans  
SC 5314 


















Table 5.2: Plasmids used within this project (plasmid maps can be found in 
Appendix 10). 
Plasmid Use Resistance Source  
pET24a Overproduction of proteins 
with an N-terminal His8-tag 
Kanamycin Epoch Life 
Sciences 
pET28a Overproduction of proteins 
with an N-terminal His6-tag 
Kanamycin Novagen 
H-MBP-3C Overproduction of proteins 
with an N-terminal His6-tag 
and MBP fusion 
Ampicillin Alexandrov 
et al.148 
pET151 Overproduction of proteins 
with an N-terminal His6-tag 
Ampicillin Thermo 
Scientific 
pET SUMO Overproduction of proteins 
with an N-terminal His6-tag 
and SUMO fusion 
Kanamycin Thermo 
Scientific 
pGPI-SceI Suicide plasmid for 
introducing a targeted I-SceI 




pRK 2013 Plasmid vehicle for DNA 
transposition 
Kanamycin Figurski and 
Helinski149 
pDAI-SceI Yeast homing endonuclease 
I-SceI expression vector 
Tetracycline Flannagan 
et al.125 
pMLBAD Broad host range vector for 
arabinose-inducible in trans 
expression of proteins 





All media was made using deionised water (dH2O) and sterilised using an 
autoclave (121 °C, 15 min).  
 




M9 minimal media  250 mL sterile agar (6 g agar in 250 mL dH2O, 
autoclave sterilised), 40 mL 10X M9 salts (30 g 
anhydrous Na2HPO4, 15 g anhydrous KH2PO4, 
5 g NaCl and 10 g NH4Cl dissolved in 500 mL 
dH2O, autoclave sterilised), 0.4 mL 1 M MgSO4 
(in dH2O, filter sterilised), 0.4 mL 0.1 M CaCl2 (in 
dH2O, filter sterilised), 50 % sucrose (in dH2O, 
filter sterilised) and  sterile dH2O (to 400 mL) 
were all warmed to 50 °C and combined, before 
the plates were poured150. 
BSM-G media  50 mL/L 20X phosphate salts (85 g/L 
KH2PO4.3H2O and 20 g/L Na2HPO4.H2O), 50 
mL/L 20X ammonium chloride (40 g/L), 10 mL/L 
100X metal salts (20 g/L MgSO4.7H2O, 1.2 g/L 
FeSO4.7H2O, 0.3 g/L MnSO4.H2O, 0.3 g/L 
ZnSO4.7H2O and 0.1 g/L CoSO4.7H2O, light 
sensitive), 0.5 g/L CAS amino acids, 0.5 g/L 
yeast extract, 0.1 g/L nitrilotriacetic acid, 4 g/L 
glycerol and 15 g/L agar (supplemented with 
12.5 mL/L 20 % arabinose after autoclave 
sterilisation where required)151.  
Mueller Hinton media  22 g/L Mueller Hinton II broth.  
Mycobacteria media  2 g yeast extract, 2 g proteose peptone No.3, 2 
g peptone from casein (tryptic digest), 2.5 g 
Na2HPO4.12H2O, 1 g KH2PO4, 1.5 g sodium 
citrate, 0.6 g MgSO4.7H2O, 50 mL glycerol, 0.5 
g Tween 80 (+15 g/L agar for mycobacterium 




7-H9 media  5 g/L Middlebrook 7-H9 broth base was 
supplemented with 0.5 % glycerol. This was 
enriched with OADC growth supplement after 
autoclave sterilisation. 
 
5.1.4 Culture conditions  
 
Unless stated otherwise cultures were grown overnight in LB at the 
appropriate growth temperature (Table 5.1). Liquid cultures were shaken at 
180 rpm. Antibiotics, where required, were used at the working concentration 
and all antibiotic stock solutions were sterilised by filtering through a 0.2 μm 
MiniStartÒ syringe filter (sartorius), and stored at -20 °C (table 5.3). All work 
with bacteria was carried out under aseptic conditions and any work with risk 
group 2 microorganisms (Table 5.1) was carried out in a category 2 
containment laboratory equipped with a Walkers Class 2 MSC safety cabinet.  
 
Table 5.3: Antibiotics used within this project. 
Antibiotic Stock conc. Solvent Working conc.  
Kanamycin (Kan) 50 mg/mL H2O 50 µg/mL 
Ampicillin (Amp) 100 mg/mL H2O 100 µg/mL 
Trimethoprim (Tp) 50 mg/mL DMSO 50 µg/mL 
Tetracycline (Tc) 20 mg/mL 70 % EtOH 20 µg/mL 




Buffers were made using dH2O. The pH was adjusted with either HCl or NaOH 
and filtered using an EDM Millipore™ Steritop™ vacuum bottle-top filter where 
required. The loading, storage, gel filtration, HEPES buffer A, HEPES buffer B 
and crystallisation buffers were stored at 4 °C. The SDS-PAGE loading buffer 




TBE buffer  89 mM Tris-base, 89 mM boric acid, 2 mM 
EDTA, pH 8.3. 
Loading buffer  20 mM Tris-HCl, 100 mM NaCl, 20 mM 
imidazole, pH 8. 
Storage buffer  20 mM Tris-HCl, 100 mM NaCl, pH 8. 
300 mM imidazole buffer  20 mM Tris-HCl, 100 mM NaCl, 300 mM 
imidazole, pH 8. 
This buffer was diluted with storage buffer 
to give 50 mM, 100 mM and 200 mM 
imidazole buffers. 
SDS-PAGE loading buffer 
(5X) 
 250 mM Tris-HCl (pH6.8), 10 % (w/v) 
SDS, 30 % (v/v) glycerol, 10 mM β-
mercaptoethanol, 0.02 % (w/v) 
bromophenol blue. 
SDS-PAGE running buffer  25 mM Tris-base, 192 mM glycine, 0.1 % 
(w/v) SDS, pH 8.3. 
Gel filtration buffer  20 mM Tris-HCl, 150 mM NaCl, pH 8. 
HEPES buffer A  30 mM HEPES, 500 mM NaCl, 10 % 
glycerol, pH 7.5. 
HEPES buffer B  30 mM HEPES, 500 mM NaCl, 150 mM 
imidazole, 10 % glycerol, pH 7.5. 
Crystallisation buffer  10 mM HEPES, 150 mM NaCl, pH 7.5. 
300 mM sodium phosphate 
buffer 
 13.44 mL 1M Na2HPO4 and 1.56 mL 1 M 





5.3 DNA manipulation and cloning procedures 
 
5.3.1 DNA isolation and purification 
 
B. gladioli BCC1622 genomic DNA was extracted from a 5 mL overnight 
culture using the GeneJET Genomic DNA Purification Kit (Thermo Scientific), 
following the manufacturer’s recommended protocol for gram-negative 
bacteria.  
 
For extraction of plasmid DNA, overnight cultures (7 mL), with the appropriate 
antibiotic, were inoculated using single colonies of the propagating E.coli 
strain. The DNA was extracted using a GeneJET Plasmid Miniprep Kit 
(Thermo Scientific), according to the manufacturer’s instructions. 
 
Where required, DNA fragments were excised from agarose gels and purified 
using a GeneJET Gel Extraction Kit (Thermo Scientific) following the 




PCRs were carried out using an Eppindorf Mastercycler® nexus GX2 and the 














Table 5.4: Volumes of reagents used for 25 μL PCR reactions. 









2X Master Mix (GC 
Buffer, NEB) 
12.5 OneTaq Hot Start Quick-
Load 2X Master Mix (GC 
buffer, NEB) 
12.5 
10 μM Forward primer 1.25 10 μM Forward primer 1.25 
10 μM Reverse primer  1.25 10 μM Reverse primer 1.25 
DMSO (5 %) 1.25 DMSO (5 %) 1.25 
Sterile H2O 8.25-7.75 Sterile H2O 7.75  
 
* Template DNA was either B. gladioli BCC1622 genomic DNA (30 ng/μL), 
plasmid DNA (10 ng/μL, diluted with sterile H2O) or a synthetic DNA fragment 
(GenScript, 10 ng/μL, diluted with sterile H2O). 
 
The thermocycling conditions used were as follows: 
 
General PCR 
98 °C – 3 minutes 
          98 °C – 10 seconds 
X35   TA –––– 30 seconds 
          72 °C – 45-60 seconds/kb 
72 °C – 10 minutes 
4 °C   – Hold 
Colony PCR 
94 °C – 3 minutes 
          94 °C – 30 seconds 
X35   TA –––– 60 seconds 
          68 °C – 60 seconds/kb 
68 °C – 10 minutes 
4 °C   – Hold 
 
The appropriate annealing temperature (TA) for each set of primers (all of 
which were purchased from Sigma-Aldrich) was determined from gradient 
PCR trials. The product(s) of the reactions were analysed as discussed in 





5.3.3 DNA size and concentration analysis 
 
PCR products and DNA fragments were analysed by agarose gel 
electrophoresis. 1 % agarose gels were made up in TBE buffer supplemented 
with 0.01 μL/mL GelRed™ nucleic acid gel stain (Biotium). Prior to 
electrophoresis, samples were prepared by mixing with 6X DNA gel loading 
dye (with the exception of colony PCRs where the loading dye was included 
in the polymerase master mix) and the gels were run in TBE buffer at 90 V for 
60-90 min, depending on the required separation, using a Bio-Rad Sub-Cell® 
GT Cell and visualised using a UVP BioDoc-It® Imagining System. GeneRuler 
1 kb DNA ladder (Thermo Scientific) was used as a reference to predict the 
size of the DNA. When required the DNA was purified from the gel as 
discussed in section 5.3.1. 
 
DNA concentrations were determined using a Thermo Scientific™ 
NanoDrop™ Lite spectrophotometer. 
 
5.3.4 Recombinant plasmid creation 
 
5.3.4.1 Traditional cloning 
 
5.3.4.1.1 Restriction digestion 
Restriction recognition sites were included in the designed oligonucleotide 
primers, which are shown in Table 5.5, that were used in the PCRs (section 
5.3.2). The resultant DNA fragments (and required vector) were incubated with 
the appropriate restriction enzymes (Thermo Scientific), utilising the conditions 
recommended by the Thermo Scientific DoubleDigest Calculator, or incubated 
with FastDigest buffer for FastDigest enzymes. The reaction mixtures were 
incubated at 37 °C for 30 min (for FastDigest enzymes) to 1 h 30 min. The 
linearized vector was purified as described in section 5.3.3, and digested PCR 
products were purified directly using the GeneJET Gel Extraction Kit by adding 
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a 1:1 volume of binding buffer to the digestion reaction, and then proceeding 
with the recommended protocol. 
 
Table 5.5: Oligonucleotide primers used for the creation of recombinant 
plasmids, the restriction sites used are underlined. 
























































































































* 8 % DMSO was required for the PCR reaction. 
** GenPart synthetic DNA fragments (GenScript) were used as template DNA. 
 
5.3.4.1.2 Ligation 
Each ligation reaction consisted of 50 ng of linearized vector DNA and a 4:1 
molar ratio of the digested insert to vector (in some cases this was raised to a 
ratio of 8:1 where a 4:1 ratio was unsuccessful). 1 μL of T4 DNA Ligase and 4 
μL of 5X Rapid DNA Ligation Buffer (both purchased from Roche) were also 
added, with dH2O being used to give a final volume of 20 μL. Ligation reactions 
were incubated overnight at RT. 
 
5.3.4.2 TOPO cloning 
 
TOPO cloning utilizes blunt-end PCR products with the addition of a CACC 
overhang at the 5’ end of the insert to impart directionality, so restriction 
digestion was not needed (the designed oligonucleotide primers are shown in 
Table 5.6). The Champion™ pET151 Directional TOPO® Expression Kit 
(Thermo Scientific) was used and in general the recommended protocol was 
followed, however a higher insert: vector ratio (6:1) was used, and the ligation 
reactions were incubated overnight at RT.  
 
Table 5.6: Oligonucleotide primers used for the creation of pET151 

















5.3.4.3 TA Cloning 
 
The creation of the pETSUMO-gbnC construct, for the overproduction of the 
N-terminal histidine and SUMO tagged protein, was achieved using the 
Champion™ pET SUMO Protein Expression System (Thermo Scientific) using 
the manufacturer’s recommended procedure. The kit utilises TA cloning, which 
relies on the single A residues added to the 3’ ends of the PCR product by Taq 
polymerase for ligation into the vector, which has single 3’ T residue 
overhangs, so the PCR was performed using OneTaq Hot Start Quick-Load 
2X Master Mix (GC buffer, NEB) as discussed in section 5.3.2, and the 
oligonucleotide primers used are shown in Table 5.7.  
 











5.3.4.4 Transformation of E.coli 
 
5.3.4.4.1 Chemical transformation 
To chemically competent E. coli (50 μL) was added either the ligation reaction 
(10 μL, or all 6 μL for the TOPO ligation) or plasmid DNA (1 μL). The cells 
were then incubated on ice for 20 min before being heat-shocked at 42 °C for 
30 seconds and once again returned to the ice for 20 min. 250 μL of LB was 
then added and the cells shaken, horizontally, for 1 h, before 50 and 100 μL 
were plated on LB agar plates containing the appropriate antibiotic, which 
were incubated at 37 °C overnight. For details on the purification of the 





Prior to electroporation the ligation reactions were purified. The T4 DNA ligase 
was deactivated by heating at 65 °C for 20 min, before 1/10 of the volume of 
3 M NaAc followed by 2.5X the volume of ice-cold 95 % EtOH was added. This 
was incubated at -20 °C for 5 min. The sample was then centrifuged (20 min, 
13000 rpm, 4 °C) and the supernatant removed before 250 μL of ice-cold 70 
% EtOH was added. After centrifugation (5 min, 13000 rpm, 4 °C) the 
supernatant was again removed and the precipitated DNA allowed to dry. 
 
The purified ligation reactions were dissolved in 10 μL dH2O, all of which was 
used in the transformation. For each transformation, the DNA was added to 
electrocompetent E.coli SY327 (60 μL), in an electroporation cuvette that had 
been cooled on ice. Electroporation was carried out at 1.8 kV, 100 Ω and 25 
μF using a BioRAD Gene PulsarÒ II in combination with a BioRad Pulse 
Controller Plus, and immediately after 500 μL of LB was added and the cells 
shaken, horizontally, for 45 min. Different volumes of the transformation 
reactions (50 and 100 μL) were plated across two LB agar plates (+ Tp). For 




The presence of the insert(s) was confirmed for each plasmid using restriction 
digestion (section 5.3.4.1.1), which was analysed by agarose gel 
electrophoresis (section 5.3.3), and successful recombinant plasmids were 
sequenced by GATC biotech. The sequencing samples were prepared 




Site-directed mutagenesis for the GldM11OMTACP(H153A) mutant was 
performed using the Q5® Site-Directed Mutagenesis Kit (New England 
Biolabs) following the manufacturers’ recommended protocol. The pET24a- 
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GldM11OMTACP plasmid was used as the template for the PCR and the 
oligonucleotide primers used are shown in Table 5.8.  
 
Table 5.8: Oligonucleotide primers used for the creation of the 







CAC ® TGC 
(His ® Ala) 
 
 
5.3.6 Gene deletion and complementation 
 
5.3.6.1 Gene deletion 
 
In-frame deletions in B. gladioli BCC1622 were introduced via double 
homologous recombination using the suicide plasmid pGPI and the I-SceI 
nuclease expression plasmid pDAI-SceI125. To create the pGPI plasmids, 800-
1000 bp sequences flanking each of the genes were amplified by PCR (section 
5.3.2), using the oligonucleotide primers listed in Table 5.9, and the resultant 
PCR products were cloned into the pGPI vector (section 5.3.4.1). The ligation 
reactions were transformed into E. coli SY327 by electroporation (section 
5.3.4.4.2) and the plasmids were purified and analysed as discussed in section 











Table 5.9: Oligonucleotide primers used for the creation of pGPI vectors, the 




















































* 8 % DMSO was required for the PCR reactions. 
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For each in-frame deletion, the appropriate pGPI plasmid was transformed into 
E.coli SY327, as described in section 5.3.4.4.2, and an overnight culture was 
grown (+Tp), along with overnight cultures of B. gladioli BCC1622 and E. coli 
HB101 +PRK2013 (+Kan), for triparental mating. The cultures were 
centrifuged (8 min, 4000 rpm) before the cell pellets were resuspended in 5 
mL LB with 10 mM MgCl2, this was then repeated to remove any traces of 
antibiotics. 100 μL of each re-suspension was then combined and mixed, 
before 100 μL was spread onto a nitrocellulose membrane (Millipore) placed 
on a LB agar plate with 10 mM MgCl2 which was incubated at 30 °C overnight. 
The cell mixture was removed from the filter using 1 mL sterile 0.9 % NaCl and 
this was spread across several LB plates (+PMX600 and Tp150) which were left 
to grow for 2.5 days (30 °C). A control where each component was plated 
individually was also created to ensure they could not grow on the LB plates 
(+PMX600 and Tp150). Colony PCR was used to screen for successful single-
crossover mutants and the oligonucleotide primers used can be found in Table 
5.10 (section 5.3.2).  
 
Table 5.10: Oligonucleotide primers used for colony PCR to screen for 
































* No DMSO was required for the PCR reaction. 
 
For the second homologous recombination this process was repeated but 
cultures of a successful mutant from the first step, E. coli SY327 +PDAI (+Tc) 
and E. coli HB101 +PRK2013 (+Kan) were used, with the mixture after 
triparental mating being plated on LB agar plates with the antibiotics, PMX600 
and Tc200. Colony PCR, using the oligonucleotide primers listed in Table 5.10, 
was used to identify colonies carrying the appropriate gene deletion (section 
5.3.2). The successful deletion mutants were cured of the pDAI plasmid by 
plating the cells on M9 minimal media150. The effects of the gene deletions 
were analysed as described in section 5.6.3.3. 
 
5.3.6.2 Gene complementation 
 
For genetic complementation the genes were amplified by PCR (section 5.3.2) 
using the oligonucleotide primers listed in Table 5.11, and cloned into the 
pMLBAD vector as discussed in section 5.3.4.1. The resultant plasmids were 
introduced into E. coli SY327 using electroporation (section 5.3.4.4.2) and 
transferred into the B. gladioli BCC1622 mutants using triparental mating as 
discussed in section 5.3.6.1. Mutants carrying the complementation plasmid 
were selected for using LB agar plates supplemented with PMX600 and Tp150. 
As a control for each complementation reaction, the empty pMLBAD vector 








Table 5.11: Oligonucleotide primers used for the creation of pMLBAD vectors, 

























The ability of the complemented mutants to produce gladiolin was determined 
by high-resolution LC-MS, of the MeCN extracts from BSM-G, supplemented 
with 0.25 % arabinose, agar-grown cultures. The cultures were prepared as 
described in section 5.3.6.3. 
 
5.3.6.3 Analysis of the metabolite profile of knockout mutants 
 
To examine the effects of the gene deletions on gladiolin production and the 
results of complementation, overnight cultures of the B. gladioli BBCC1622 
mutants and WT were grown, and the cells were pelleted by centrifugation (8 
min, 4000 rpm) before being resuspended in 4 mL of sterile 0.9 % NaCl. For 
each strain, a sterile cotton bud was used to draw streaks across a BSM-G 
agar plate. The plates were  incubated at 30 °C for 2.5 days. Prior to analysis 
the bacterial cells were removed from the plate and the solid medium chopped 
up into small pieces and placed in a glass vial. 4 mL of MeCN was added and 
this was shaken and left for 1 h, before the supernatant was filtered using 0.45 
µm nylon micro-centrifugal filters (Thermo Scientific) and analysed by high-
resolution LC-MS as described in section 5.3.6.4. 
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5.3.6.4 High-resolution LC-MS 
 
High-resolution LC-MS was performed using a Bruker MaXis™ Impact Ultra-
High Resolution ESI-Q-TOF instrument (ESI in positive ion mode; full scan 50-
2500 m/z; end plate offset, -500 V; capillary, -4500 V; nebulizer gas (N2), 1.4 
bar; dry gas (N2), 8 L/min and dry temperature, 200 °C) connected to a Dionex 
UltiMate 3000 UHPLC fitted with a ZORBAX Eclipse Plus C18 column (1.8 
µm, 2.1 x 100 mm, Agilent). The UHPLC elution profile is detailed in Table 
5.12 and the absorbance was monitored at 210 and 254 nm. Calibration was 
performed with 10 mM sodium formate through a loop injection of 20 µL at the 
start of each run.  
 
Table 5.12: Elution conditions for high-resolution LC-MS analysis. 
Time  
(mins) 
H2O / 0.1 % FA  
(%) 




0.0 95 5 0.2 
5.3 95 5 0.2 
17.3 0 100 0.2 
22.3 0 100 0.2 
25.3 95 5 0.2 
33.3 95 5 0.2 
 
5.4 Isolation and characterisation of amide gladiolin 
 
5.4.1 Production and purification of gladiolin and amide gladiolin 
 
For the production of amide gladiolin and gladiolin, 5 mL overnight cultures of 
B. gladioli BCC1622DgbnM and B. gladioli BCC1622 WT, respectively, were 
pelleted by centrifugation (8 min, 4000 rpm) and the pellets resuspended in 4 
mL of sterile 0.9 % NaCl. For each strain, a sterile cotton bud was used to 
draw streaks across 30 BSM-G agar plates (1 L of medium) which were 
incubated at 30 °C for 2.5 days. Prior to extraction the bacterial cells were 
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removed from the plates and the solid medium was chopped into small pieces. 
To extract the metabolites of interest the small pieces of solid medium were 
covered with ethyl acetate. This was left for 2 h at RT before being filtered and 
dried in vacuo. The solid medium was again covered with ethyl acetate and 
the extraction process repeated, yielding a dark brown crude extract. 
High-performance liquid chromatography (HPLC) was used to purify the 
antibiotics, and was carried out using an Agilent Technologies 1260 Infinity LC 
system fitted with an ELSD and fraction collector. The crude extracts were first 
dissolved in a minimum volume of MeOH and loaded onto dental cotton tubes 
that were dried in vacuo. The dried dental cotton was put into a cartridge 
before being loaded onto a BETASIL C18 column (150 x 21.2 mm, Thermo 
Scientific). The HPLC elution profile is detailed in Table 5.13. The fractions 
containing the pure antibiotics were identified using high-resolution LC-MS 
(section 5.3.6.4), and the desired fractions for amide gladiolin were dried using 
a Genevac EZ-2 (SP Scientific), and for gladiolin using a ScanVac CoolSafe 
freeze dryer (LaboGene). This yielded amide gladiolin (14 mg) and gladiolin 
(18 mg) as white solids. 
 
Table 5.13: Elution conditions for HPLC purification of amide gladiolin and 
gladiolin. 
Time (mins) H2O (%) MeCN (%) Flow rate (mL/min) 
0 65 35 9 
5 65 35 9 
50 35 65 9 
51 0 100 9 
55 0 100 9 
56 65 35 9 







5.4.2 NMR spectroscopy 
 
High-field 1- and 2-D NMR spectra for structure elucidation were recorded 
using a Bruker Avance III 600 MHz instrument. The instrument operated at 
600 MHz for 1H NMR and 150 MHz for 13C NMR with all spectra being 
recorded at 298 K. Purified amide gladiolin (14 mg) was dissolved in 230 µL 
of DMSO-d6 (Sigma Aldrich) and the 1H and 13C NMR chemical shifts were 
referenced to the solvent peaks at dH 2.50 and dC 39.5, respectively. For iso-
amide gladiolin the NMR analysis was performed using 5 mg dissolved in 230 
µL of DMSO-d6.  Bruker Topspin 2.1 software was used to process the spectra. 
The assignments for amide gladiolin can be found in Table 3.1 and the 
assignments for iso-amide gladiolin can be found in table S1 (appendix 8). 
 
5.4.3 Stability analysis 
 
Amide gladiolin and gladiolin were dissolved in MeOH (1 mg/mL) and left at 
15 °C for 0, 6, 24, 48 and 96 h, prior to high-resolution LC-MS analysis (section 
5.3.6.4). 
 
5.5 Protein overproduction, purification & characterisation 
 
5.5.1 Protein overproduction 
 
For protein overproduction, 1 μL of plasmid DNA was used to chemically 
transform the chosen E.coli  strain (section 5.3.4.4.1). One colony was picked 
and a 10 mL overnight culture grown, which was used to inoculate 1 L of LB 
(in a 5 L conical flask) that was supplemented with the appropriate antibiotic. 
This was grown until the OD600 = 0.6-0.8. The culture was then cooled before 
the inducer, IPTG (1 M stock dissolved in sterile dH2O, stored at -20 °C), was 
added. The culture was left overnight at 15 °C (180 rpm). A comprehensive 
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list of the N-terminal his-tagged proteins produced as part of this study, and 
details of the precise expression conditions can be found in Table 5.14. 
 
Table 5.14: Overproduction conditions for recombinant proteins. Rows in blue 
indicate that the overproduced protein was insoluble. 














































Kan C43 0.5 mM 
GldM11ACP(II) pET28a-
GldM11ACP(II) 















Kan BL21 0.5 mM 
MisM1OMT pET28a-MisM1OMT 
(This study) 
Kan BL21 0.5 mM 
Pfs pET151-pfs 
(This study) 
Amp BL21 1 mM 
PanK pET29b-panK 
(Tosin et al.152) 
Kan BL21 0.5 mM 
PPAT pET29b-PPAT 
(Tosin et al.152) 
Kan BL21 0.5 mM 
DPCK pET20b(+)-DPCK 
(Tosin et al.152) 
Amp BL21 1 mM 
Sfp pET28a-sfp 
(Kindly provided by 
Dr M. Tosin) 
Kan BL21 1 mM 
GbnM pET28a-gbnM 
(This study) 




























Amp C43 0.5 mM 


















* Synthetic constructs were purchased from Epoch Life Sciences and were 
designed with an octa-histidine tag. 
 
5.5.2 Protein purification 
 
The cells were harvested from the culture using centrifugation (30 min, 5000 
rpm, 4 °C) and the cell pellets were resuspended in loading buffer (10 mL/L). 
The cells were lysed using a Constant Systems Ltd TS-Series Cabinet cell 
disruptor, set to a pressure of 20 psi, and the cell debris was removed by 
centrifugation (40 min, 17000 rpm, 4 °C). The supernatant was filtered using 
a 0.45 μm syringe filter (GE Healthcare), before being applied to a 1 mL 
HiTrapÔ HP affinity column (GE Healthcare), which was washed with 15 mL 
loading buffer. The protein was then eluted from the column in a stepwise 
approach by first using 50 mM imidazole buffer (5 mL), followed by 100 mM 
imadazole buffer (3 mL), 200 mM imadazole buffer (3 mL) and finally 300 mM 
imadazole buffer (3 mL).  
 
The fractions containing the protein (as determined by SDS-PAGE analysis, 
section 5.5.3) were pooled and concentrated to 1-2 mL, using an Amicon® 
Ultra Centrifugal Filter (Millipore) with the appropriate molecular weight cut-off 
(4000 rpm, 4 °C), before being buffer exchanged by the addition of 15 mL of 
storage buffer and concentrated to approximately 250-500 µL. Glycerol was 
added to give a 10 % final concentration and the proteins were divided into 




5.5.3 SDS-PAGE analysis 
 
SDS-PAGE gels were prepared as shown in Table 5.15. 
 
Table 5.15: Volumes of reagents used in the preparation of SDS-PAGE gels. 
 Stacking gel 
(1 mL) 


















H2O 0.68 2.3 1.9 1.6 1.1 
30 % Acrylamide mix 0.17 1.3 1.7 2.0 2.5 
1.0 M Tris (pH 6.8) 0.13 - - - - 
1.5 M Tris (pH 6.8) - 1.3 1.3 1.3 1.3 
10 % SDS 0.01 0.05 0.05 0.05 0.05 
10 % APS 0.01 0.05 0.05 0.05 0.05 
TEMED 0.001 0.003 0.002 0.002 0.002 
 
Protein samples were prepared by mixing 20 μL of each fraction (pure protein 
samples were first diluted to 100 ng/ μL with loading buffer) with 5 μL 5X SDS-
PAGE loading buffer. 10 μL of each sample was loaded onto the gel, along 
with PageRuler™ Plus Prestained Protein Ladder (4 µL, Thermo Scientific) 
which was used as a molecular weight standard. Gels were run using a Mini-
PROTEAN® Tetra cell (Bio-Rad, 180 V, 50 min), stained with EZBlue™ gel 











5.5.4 Determining protein concentration 
 
In general protein concentrations were determined by measuring the 
absorbance at 280 nm, using a Thermo Scientific™ NanoDrop™ Lite 




A is the absorbance, l is the pathlength (1 cm) and e is the extinction coefficient 
as determined by the ExPASy ProtParam tool. 
 
For GldM11ACP(II) and MisM9ACP(II) the proteins did not have extinction 
coefficients, so the protein concentrations were determined using the Bradford 
assay. The Quick StartÔ Bradford Protein Assay Kit (BIO-RAD) was used 
according to the manufacturer’s recommended protocol using BSA as the 
protein standard. A Thermo BioMate™ 3 UV-Vis spectrophotometer was used 
to measure the absorbances at 595 nm. 
 
5.5.5 Determining protein oligomerisation state 
 
To determine protein oligomerisation states SEC, which separates proteins in 
solution based on their size, was used. SEC was performed using an AKTA 
pure chromatography system fitted with a GE Healthcare HiLoad® 16/600 
Superdex® 200 pg column. Gel filtration buffer was used as the mobile phase 
(1.2 column volumes per run) with a flow rate of 1 mL/min. A protein standard 
consisting of 6 mg of thyroglobin (669 kDa), 6 μL of apopferritin (443 kDa), 3 
mg of β-amylase (200 kDa), 1 mg of BSA (66 kDa) and 1 mg of lysozyme (14.3 
kDa) was made up in 200 μL of gel filtration buffer and was run first through 
the column to give a comparison between protein mass and retention time 
under the conditions of the experiment. Approximately 3 mg of the protein of 





5.5.6 Intact protein MS 
 
All proteins were diluted with HPLC grade H2O to a concentration of 10-20 μM 
for analysis on the Bruker MaXis™ II Ultra-High Resolution ESI-Q-TOF 
instrument (ESI in positive ion mode; full scan 50-2500 m/z; end plate offset, 
-500 V; capillary, -4500 V; nebulizer gas (N2), 1.4 bar; dry gas (N2), 8 L/min 
and dry temperature, 200 °C) connected to a Dionex 3000 RS UHPLC fitted 
with an ACE C4-300 RP column (100 x 2.1 mm, 5 μm, 30 °C). The UHPLC 
elution profile is detailed in Table 5.16. 
 
Table 5.16: Elution conditions for intact protein MS. 
Time  
(mins) 
H2O / 0.1 % FA  
(%) 




0.0 95 5 0.2 
5.0 95 5 0.2 
35.0 0 100 0.2 
40.0 0 100 0.2 
45.0 95 5 0.2 
 
5.6 Protein crystallisation trials 
 
5.6.1 Protein overproduction and purification 
 
For protein crystallisation trials a large volume of high-purity protein was 
required. Protein overproduction was carried out on a large scale (3 L, 1 L per 
5 L flask), but was otherwise performed as discussed in section 5.5.1. The 
cells were harvested by centrifugation (30 min, 5000 rpm, 4 °C) and the cell 
pellets were resuspended in HEPES buffer A (10 mL/L of culture), before the 
resuspended cells were added to a SONOPULS rosett cell RZ 3 (BANDELIN) 
which was placed on ice. The cells were lysed by sonication (amplitude: 50, 3 
min, 3 pulsar, X3) and the lysate was clarified by centrifugation (40 min, 17000 
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rpm, 4 °C). The cell free extract was then passed through a 0.45 μm syringe 
filter. 
 
Protein purification was performed using an AKTA pure chromatography 
system, fitted with a F9-C fraction collector, using a flow rate of 1 mL/min. First, 
the protein was loaded onto a 1 mL HiTrapÔ HP affinity column, which was 
washed with 25 mL 10 % HEPES buffer B (90 % HEPES buffer A). The protein 
was then eluted from the column by increasing the concentration of HEPES 
buffer B to 100 % over 15 mL (collecting 2 mL fractions). The fractions 
containing the protein (as determined by SDS-PAGE analysis, section 5.5.3) 
were pooled and concentrated to 2 mL, using an Amicon® Ultra Centrifugal 
Filter (Millipore) with the appropriate molecular weight cut-off (4000 rpm, 4 °C). 
The protein was then further purified and buffer exchanged using SEC (see 
section 5.5.5, crystallisation buffer). The protein was loaded onto the SEC 
column using a 2 mL loop and 2 mL fractions were collected when a peak was 
detected. The fractions containing the protein were concentrated to 10 mg/mL. 
The protein was stored at 4 °C between experiments, and some protein was 
flash frozen in liquid nitrogen and stored at -80 °C for use in assays. 
 
5.6.2 Crystallisation trials 
 
To the purified protein, SAM (150 mM, dissolved in 1 M HEPES, pH 7.5) was 
added to give a final concentration of 2 mM. The protein was then used to set 
up 100 nL sitting drop crystallisation trials using a mosquitoÒ LCP robot 
(ttplabtech). Seven 96-well commercially-available crystallisation screens 
(JCSG cores I-IV, PACT premier, MorpheusÒ and SG1Ô, purchased from 
Molecular Dimensions) were trialled, testing both a 1:1 protein: buffer ratio and 
a 2:1 protein: buffer ratio. The crystallisation trials were incubated at both RT 






5.6.3 Cleavage of the hexahistidine tag 
 
The His-tag was cleaved from GldM11OMT after purification by Ni-NTA (which 
was carried out as described in section 5.6.1). The protein (3 mL) was 
incubated with thrombin protease (1 U/µL, Sigma Aldrich) so that there was 1 
U/ 100 µg of protein to be cleaved, and left for 16 h at 4 °C. Successful 
cleavage was confirmed by SDS-PAGE analysis (section 5.5.3) and the 
cleavage reaction was passed over a column (0.5 mL/min flow rate) packed 
with half benzamidine sepharose (which binds thrombin protease) and half Ni-
NTA (which binds any protein where the His-tag had not been cleaved), 
washing with 10 mL HEPES buffer A. The flow through was concentrated 
using an Amicon® Ultra Centrifugal Filter (Millipore) with the appropriate 
molecular weight cut-off (4000 rpm, 4 °C), before the protein was purified to 
homogeneity by SEC chromatography as described in section 5.6.1, and used 




5.7.1 Biochemical assays 
 
5.7.1.1 Methylation assays 
 
The composition of the methylation assays is shown in Table 5.17. In order to 
prevent a significant lowering of the pH of the assay, SAM iodide (Sigma-
Aldrich) was dissolved in 300 mM phosphate buffer (pH 7.8) to give a 20 mM 
stock solution (stored at -80 °C) and the 80 mM aqueous ATP stock solution 
was adjusted to pH 7 using NaOH. All components of the assay except for 
SAM were added to the reaction, with the pantetheine substrate (dissolved in 
DMSO) being added last. The assay was mixed by pipetting up and down and 
incubated for 1 h at RT to allow the substrate to be loaded onto the ACP 
domain. SAM was then added, and the assay mixed before being incubated 
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for a further 1 h 30 min (RT). For each pantetheine substrate, and for each 
OMT-ACP didomain, the assay was repeated in triplicate with controls being 
performed by adding the appropriate volume of storage buffer in place of SAM. 
 
Table 5.17: The composition of the methylation assays. The * indicates that 
the assay component acts catalytically. 
Component Concentration Volume 
OMT-ACP Protein 100 µM 10-14 µL 
Pantetheine substrate 800 µM 2 µL 
PanK 8 µM * 1 µL 
PPAT 8 µM * 1 µL 
DPCK 8 µM * 5 µL 
ATP 4 mM 2.5 µL 
Sfp 10 µM * 2 µL 
MgCl2 10 mM 5 µL 
SAM 600 µM 1.5 µL 
Storage buffer - to 50 µL 
 
The assays were then diluted with HPLC grade water, so that the final 
concentration of the OMT-ACP protein was 10-18 µM, before being analysed 
using intact protein MS (see section 5.5.6). 
 
5.7.1.2 Transacylation assay 
 
First, the apo-ACP domains, GldM11ACP(I) and GldM11ACP(II), were 
converted to (S)-3-hydroxyoctanoyl- holo-GldM11ACP(I) and holo-
GldM11ACP(II), respectively. The reactions were set up as shown in Table 
5.18, and incubated at RT for 1 h 30 min. Following incubation, excess CoA 
or pantetheine substrate were removed by buffer exchanging into storage 
buffer using Amicon Ultra centrifugal filters with a 3 kDa MWCO membrane 





Table 5.18: The composition of the ACP domain loading reactions. The * 
indicates that the assay component acts catalytically. 
Loading of GldM11ACP(I) Loading of GldM11ACP(II) 
Component Volume Component Volume 
ACP protein (200 µM) 71 µL ACP protein (200 µM) 25 µL 
3-hydroxyoctyl pantetheine 
(600 µM) 
2 µL CoA (500 µM) 1.26 µL 
PanK (10 µM *) 1.5 µL Sfp (10 µM *) 4 µL 
PPAT (10 µM *) 1.5 µL MgCl2 (10 mM) 10 µL 
DPCK (10 µM *) 5 µL   
ATP (4 mM) 5 µL   
Sfp (10 µM *) 4 µL   
MgCl2 (10 mM) 10 µL   
Storage buffer to  
100 µL 
Storage buffer to  
100 µL 
 
The transacylation assay was then carried out by combining (S)-3-
hydroxyoctanoyl- holo-GldM11ACP(I) (100 µM) and holo-GldM11ACP(II) (100 
µM) with GldM11KSOMT (25 µM) in storage buffer (100 µL final volume). A 
control reaction was performed by adding the appropriate volume of storage 
buffer in place of GldM11KSOMT. The reactions were incubated at RT for 3 h 
before the reaction mixtures were diluted 10-fold in HPLC grade water for 
analysis by intact protein MS (see section 5.5.6). The assay was repeated in 
triplicate. 
 
5.7.1.3 ACP-OMT interaction assays 
 
For the ACP-OMT interaction assays the apo-ACP domains were loaded with 
either (S)-3-hydroxyoctanoyl- or (R)-3-hydroxyoctanoyl-pantetheine to assess 
interactions with GldM11OMT and MisM1OMT, respectively. The ACP 
domains were loaded with the pantetheine substrate as shown in Table 5.18 
for GldM11ACP(I). The holo-form of the ACP domains (40 µM) were then 
incubated with the OMT domain (80 µM), the S-adenosylhomocysteine 
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nucleosidase, Pfs (1 µL), to prevent potent inhibition of the OMT domain by 
SAH, and SAM (600 µM) in storage buffer (total volume 50 µL), for 2 h at RT. 
The assays were diluted with HPLC grade water to give a final ACP domain 
concentration of 10 µM, before being analysed by intact protein MS (see 
section 5.5.6). Control reactions were performed by adding the appropriate 
volume of storage buffer in place of SAM. Where no ACP-OMT domain 
interactions could be observed, the assays were repeated with 160 µM OMT 
domain, to ensure that the assays contained no potential bias that could occur 
due to any error in the calculated protein concentrations.  
 
5.7.1.4 GbnM activity assay 
 
This assay was conducted using cell lysate. To prepare the cell lysate pET28a-
gbnM and the empty expression vector, pET28a, were separately transformed 
into E. coli BL21 (section 5.3.4.4.1). Protein overproduction was performed on 
a small scale (10 mL LB in a sterile 50 mL Falcon™ tube), but was otherwise 
performed as discussed in section 5.5.1. IPTG was also added to the pET28a 
control for consistency. The cells were collected from the cultures by 
centrifugation (15 min, 4000 rpm) and the cell pellets were resuspended in 400 
µL storage buffer prior to the cells being lysed by sonication (amplitude: 30, 2 
min, 2 pulsar, on ice). The resultant lysates were used directly in the assay 
and 10 % SDS-PAGE analysis was performed to assess the composition of 
the lysates (section 5.5.3). 
 
For the assay, each of the lysates (5 µL, 10 % of the final volume) was 
combined with amide gladiolin, which was dissolved in DMSO (2 µL, 800 µM) 
and made up to a total volume of 50 µL with storage buffer. Standards of amide 
gladiolin and gladiolin were created by adding the antibiotic to storage buffer 
in the absence of lysate. The reactions were incubated at RT for 3 h, before 
100 µL of MeCN was added to precipitate the proteins, which were removed 
by centrifugation (5 min, 13000 rpm). The supernatants were filtered using 
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0.45 µm nylon micro-centrifugal filters (Thermo Scientific™), before being 
analysed by high-resolution LC-MS (section 5.3.6.4). 
 
5.7.1.5 AT domain loading assays 
 
Stocks of acetyl-, succinyl- and malonyl-CoA (20 mM in HPLC grade water) 
were flash frozen and stored at -80 °C. 20 mM succinamic acid was also 
prepared in HPLC grade water and was pH adjusted, using concentrated 
NaOH (pH 7). Succinamic-CoA was made by combining the CoA transferase, 
VbxP (150 µM, supplied by Christian Hobson), acetyl-CoA (1.5 mM), 
succinamic acid (6 mM) and storage buffer in a final volume of 100 µL. A boiled 
enzyme control (10 min, 95 °C) was also performed. After overnight incubation 
at RT, 30 µL of the assay was added to 60 µL MeOH to precipitate the enzyme, 
and the precipitant was removed by centrifugation (5 min, 13000 rpm). 
Complete conversion of acetyl-CoA to succinamic-CoA was confirmed by 
high-resolution LC-MS (section 5.3.6.3). VbxP was removed from the 
remainder of the assay using an Amicon Ultra-0.5 mL centrifugal filter with a 3 
kDa MWCO (Millipore) and the flow through was used directly in future assays.  
 
To investigate the substrate tolerance of GbnB, compared to the malonyl-
specific AT domains EtnK and PksC (supplied by Dr Mathew Jenner), the AT 
domains (60 µM) were incubated with either succinyl-CoA, succinamic-CoA or 
malonyl-CoA (240 µM) in storage buffer (50 µL final volume). After 15 min, the 
assays were diluted with HPLC grade water, so that the final concentration of 
the AT domains was 15 µM, before being analysed by intact protein MS 
(section 5.5.6). Control reactions were performed by eliminating the CoA 
derivatives, which for succinamic-CoA involved using the supernatant of the 
boiled VbxP reaction to ensure that succinamic acid was not capable of self-






5.7.2 Antimicrobial activity assays 
 
5.7.2.1 Broth microdilution method 
 
In general MICs were determined using the broth microdilution method 
(National Committee for Clinical Laboratory Standards, document M7-A7153). 
Overnight cultures of the test strains (refer to Table 5.1) were grown in 5 mL 
Mueller Hinton media at 30 °C. The antibiotics were dissolved in DMSO to a 
concentration of 5 mg/mL. In a 96-well microtiter plate 50 μL of serial 2-fold 
dilutions of the antibiotic (128 μg/mL - 0.0025 μg/mL) in Mueller Hinton media 
were mixed with 50 μL of microbial suspension that was made up, from the 
overnight cultures, to McFarland standard No. 0.5 and then diluted 100-fold, 
also in Mueller Hinton media. The assays were incubated for 16 h at 30 °C, 
and the MIC was defined as the lowest concentration that visibly inhibited 
bacterial growth. Each assay was performed in triplicate. 
 
5.7.2.2 Resazurin microtiter assay 
 
MICs against M. smegmatis were determined using the rezasurin microtiter 
assay130. A culture of M. smegmatis was grown in mycobacteria media for 2 
days at 37 °C while being shaken at 220 rpm. In a 96-well microtiter plate 50 
μL of a bacterial suspension made up to McFarland standard No. 1, in 7H-9 
media and diluted 20-fold was mixed with 50 μL of serial 2-fold dilutions of the 
antibiotic (128 μg/mL - 0.0025 μg/mL) also in 7H-9 media (initially the antibiotic 
was dissolved in DMSO to a concentration of 5 mg/mL). The assays were 
incubated at 37 °C for 2.5 days. 15 μL of resazurin solution (Acros Organics, 
made to a 0.01 % weight/volume solution in sterile water) was then added to 
each well and incubated overnight, the MIC was defined as the lowest 
concentration to prevent a complete colour change from blue to pink. Each 
assay was performed in triplicate and controls were carried out to ensure that 




5.8 Computational methods 
 
5.8.1 ClusterTools searches 
 
ClusterTools78 was used to search for embedded OMT domains from PKSs. 
First the MiBIG database79 (constructed on 03-09-2016 by Dr Emzo de los 
Santos) was searched for embedded OMT domains from trans-AT PKSs using 
the custom HMM rule ‘OMT and PKS_KS and not PKS_AT’ using the PKS 
annotation HMMs from antiSMASH72. The default parameters were not able 
to clearly distinguish OMT domains from CMT domains, so the HMM search 
E-value was set to 1.0e-30. Using the adjusted parameters this database was 
then searched for embedded OMT domains from cis-AT PKS by specifying 
that an OMT, PKS_KS and PKS_AT were all required. To look for additional 
and cryptic clusters containing embedded OMT domains these two searches 
were then performed on a database made from all reference and 
representative genomes from NCBI (created on 05-12-2017 by Dr Emzo de 
los Santos).  
 
ClusterTools was also used to search these two databases for BGCs that 
contained homologues of the putative asparagine synthetase, gbnC, and the 
putative amidase gbnM, from the gladiolin biosynthetic pathway. To do this the 
protein sequences of the genes were manually imputed to be used in a query 
that specified that both of these genes were required. Using the default 
parameters ClusterTools identified three biosynthetic clusters, the 
etnangien66, sorangicin147 and fosfazinomycin123 clusters, from the MiBIG 
database. When searching the NCBI database it was also specified that a 







5.8.2 Sequence alignments 
 
All multiple sequence alignments were generated using ClustalX 2.1 by 
performing a complete alignment with default parameters101. The protein 
sequences used were retrieved from either the MIBiG repository79 or NCBI 
databases.  
 
5.8.3 Phylogenetic analysis 
 
The phylogenetic trees presented in this study were also created using  
ClustalX 2.1101, from the generated sequence alignments using the neighbour 
joining clustering algorithm. The resultant phylogenetic trees were visualised 
using FigTree v1.4.3, from which the presented images were generated.  
 
5.8.4 Homology modelling of GldM11OMT 
 
The homology model of GldOMT was constructed using the intensive 
modelling mode of Phyre2 89. The published structures of the cyclopropane 
fatty acid synthase (6BQC)154, pavine (5KN4)155 and coclaurine (6GKV)156 
NMTs and the mycolic acid cyclopropane synthases CmaA1 (1KPG), CmaA2 
(1KPI) and PcaA (1L1E)157 were used as templates. To assess the quality of 
the model a Ramachandran plot was produced using the RAMPAGE server. 
SAH was added to the active site by aligning the model to the published 
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Appendix 1: Protein sequences and characterization by MS 
 
For proteins overproduced using the pET28a vector post-translational 
cleavage of the N-terminal methionine, by methionine aminopeptidases, 
occurs. The His-tag also becomes gluconoylated; the peaks in the MS 
corresponding to this are marked with a *. Mutated residues are shown in red 
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MKHHHHHHHH GGLVPRGSHG SEASPAWTGG TGGTGGPGDK AAEYYTFDAQ RRSDTYHEEY  
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LTFCPFEREQ PGFSMTRVLS APEAYPDEYR QVLDKQKEMR AVTFRHERFE RVGRVLDIGC  
 
       130        140        150        160        170        180  
GCGSDLIELA LRHPALHADG FTITPAQAEL GNRRIANLGI AERVRIRHAD SSRDAFPHRY  
 
       190        200        210        220        230        240  
DLVIGFEVSC HIADKTALFS NIRRSLAPTG CILLMDFIAN LRGSIVDDKV DIAISPQAEW  
 
       250        260        270        280        290        300  
ANVLAEQGLV IDDLVDLSEG IANYVFDPDV ERNIAHFPEA ARRSSRNFAN MAVSLRQNWI  
 
       310        320        330        340        350        360  
SYCLFRIVVD RHGRSTEALR AANAAVIARR TPYREALADL FARRDGSGDI GLTAAVMAAA  
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SRQAPAREAA KEAVQQAAPA PQPAAAPSAG ARAATVREAL ERVMIDTLGV SPAELRAARS  
 
       430        440        450        460        470        480  
FAELGVDSLL AVRLLEAINV AFDLHEPTSV MFEFHDTQAL AAHLETRGAR VAALPAEAAV  
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Figure S2: Raw and deconvoluted ESI-MS spectra for GldM11OMT-




        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MGGPGDKAAE YYTFDAQRRS DTYHEEYLTF CPFEREQPGF  
 
        70         80         90        100        110        120  
SMTRVLSAPE AYPDEYRQVL DKQKEMRAVT FRHERFERVG RVLDIGCGCG SDLIELALRH  
 
       130        140        150        160        170        180  
PALHADGFTI TPAQAELGNR RIANLGIAER VRIRHADSSR DAFPHRYDLV IGFEVSCHIA  
 
       190        200        210        220        230        240  
DKTALFSNIR RSLAPTGCIL LMDFIANLRG SIVDDKVDIA ISPQAEWANV LAEQGLVIDD  
 
       250        260        270        280        290        300  
LVDLSEGIAN YVFDPDVERN IAHFPEAARR SSRNFANMAV SLRQNWISYC LFRIVVDRHG  
 
       310        320        330        340        350  













Figure S4: Raw and deconvoluted ESI-MS spectra for GldM11OMT after 






        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MDQGGVAIIG VSVRTAGAND AGELWELLRS GRRAIGEVPA  
 
        70         80         90        100        110        120  
SRWDWRPYFS GPGEASNRIA THRGAFIEGL DGFDPLFFEI SPREAQWMDP RQRLILEEAW  
 
       130        140        150        160        170        180  
RAFEDAGYAG ERLRGSRCGV FVGVEEGVPG EAADGLATSH HNGILAARIS YVLDLKGPNL  
 
       190        200        210        220        230        240  
AINTACSSGL VAVHTACQSV QRGECELALA GGVNVLNSPL TYVALTQGGM LSSSGECHAF  
 
       250        260        270        280        290        300  
DARADGMVPG EAVAAVVLKD LARAQADGDP IHGVIRASGV NYDGRTNGIT APSARSQRAL  
 
       310        320        330        340        350        360  
ISEVLERGGI EAERIEAVLA HSVGSPLGDP IEARALCEAL GEGLGEGLNE GLNEGTQTRV  
 
       370        380        390        400        410        420  
LGSVKPQIGH TFAASGVVNV IAMCASLRHG LRLGIANHEV ANPDLRIGDG ALSLGAGAQP  
 
       430        440        450        460        470        480  
WPKRAGVARC GLVSATGMSG TNACVVIEEA PEETSGAVGK ETRREWLVKL SARESGALRE  
 
       490        500        510        520        530        540  
SARRLRAWLG GEAGAEVELD ALSLTLDVGR EAMRYRLAMV VGAGGSEEGR SGLMAALDAY  
 
       550        560        570        580        590        600  
LEGAEGAALA GKGVYAGEVA DEGMEEAGSA ALSKASALSG QARDWCEGLR TDDAVLHRGG  
 
       610        620        630        640        650        660  
RPRRLAGLPT YPFARRPLGQ PPAAEASPAW TGGTGGTGGP GDKAAEYYTF DAQRRSDTYH  
 
       670        680        690        700        710        720  
EEYLTFCPFE REQPGFSMTR VLSAPEAYPD EYRQVLDKQK EMRAVTFRHE RFERVGRVLD  
 
       730        740        750        760        770        780  
IGCGCGSDLI ELALRHPALH ADGFTITPAQ AELGNRRIAN LGIAERVRIR HADSSRDAFP  
 
       790        800        810        820        830        840  
HRYDLVIGFE VSCHIADKTA LFSNIRRSLA PTGCILLMDF IANLRGSIVD DKVDIAISPQ  
 
       850        860        870        880        890        900  
AEWANVLAEQ GLVIDDLVDL SEGIANYVFD PDVERNIAHF PEAARRSSRN FANMAVSLRQ  
 
       910        920        930        940        950        960  














       10         20         30         40         50         60  
MGSSHHHHHHS SGLVPRGSHM NRSESTRPDQ GGVAIIGVSV RTAGANDAGE LWELLRSGRR  
 
        70         80         90        100        110        120  
AIGEVPASRW DWRPYFSGPG EASNRIATHR GAFIEGLDGF DPLFFEISPR EAQWMDPRQR  
 
       130        140        150        160        170        180  
LILEEAWRAF EDAGYAGERL RGSRCGVFVG VEEGVPGEAA DGLATSHHNG ILAARISYVL  
 
       190        200        210        220        230        240  
DLKGPNLAIN TACSSGLVAV HTACQSVQRG ECELALAGGV NVLNSPLTYV ALTQGGMLSS  
 
       250        260        270        280        290        300  
SGECHAFDAR ADGMVPGEAV AAVVLKDLAR AQADGDPIHG VIRASGVNYD GRTNGITAPS  
 
       310        320        330        340        350        360  
ARSQRALISE VLERGGIEAE RIEAVLAHSV GSPLGDPIEA RALCEALGEG LGEGLNEGLN  
 
       370        380        390        400        410        420  
EGTQTRVLGS VKPQIGHTFA ASGVVNVIAM CASLRHGLRL GIANHEVANP DLRIGDGALS  
 
       430        440        450        460        470        480  
LGAGAQPWPK RAGVARCGLV SATGMSGTNA CVVIEEAPEE TSGAVGKETR REWLVKLSAR  
 
       490        500        510        520        530        540  




       550        560        570        580        590        600  
MAALDAYLEG AEGAALAGKG VYAGEVADEG MEEAGSAALS KASALSGQAR DWCEGLRTDD  
 
       610        620        630        640        650        660  
AVLHRGGRPR RLAGLPTYPF ARRPLGQPPA AEASPAWTGG TGGTGGPGDK AAEYYTFDAQ  
 
       670        680        690        700        710        720  
RRSDTYHEEY LTFCPFEREQ PGFSMTRVLS APEAYPDEYR QVLDKQKEMR AVTFRHERFE  
 
       730        740        750        760        770        780  
RVGRVLDIGC GCGSDLIELA LRHPALHADG FTITPAQAEL GNRRIANLGI AERVRIRHAD  
 
       790        800        810        820        830        840  
SSRDAFPHRY DLVIGFEVSC HIADKTALFS NIRRSLAPTG CILLMDFIAN LRGSIVDDKV  
 
       850        860        870        880        890        900  
DIAISPQAEW ANVLAEQGLV IDDLVDLSEG IANYVFDPDV ERNIAHFPEA ARRSSRNFAN  
 
       910        920        930        940        950        960  
MAVSLRQNWI SYCLFRIVVD RHGRSTEALR AANAAVIARR TPYREALADL FARRDGSGDI  
 
       970        980        990       1000       1010       1020  
GLTAAVMAAA SRQAPAREAA KEAVQQAAPA PQPAAAPSAG ARAATVREAL ERVMIDTLGV  
 
      1030       1040       1050       1060       1070  














        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MASGEEKSDV EPRIDHTLDE NKAVEFYTRM TQDCDEAFQE  
 
        70         80         90        100        110        120  
EYLTFGAFPR RIPGFSMTRV AMNAERYPEE LEMIKESQRE LRQVLFCRED FDRVHTFLDI  
 
       130        140        150        160        170        180  
GCGHGTDVIQ VAALYPHIQT HGFTITESQA ILGNRRIEHM NLGSRARIYH KDSSKEPFPD  
 
       190        200        210        220        230        240  
NCDMILGIEV TFHIRDKDAL LQKMADALSD DGKILLMDYI ANLRGSIVDP NVEISIPTQS  
 
       250        260        270        280        290        300  
QWIDLLSQHD LIIDEIIDVS TEVSNYLYDP EHAEHTKHLP KVSQDSYRNY ANQAIALEKG  
 
       310        320        330        340        350        360  
WITYCLLKLQ RDTQRSEQER REYNAWKIAN QTPYAQALED MLRVGRMPYP LSGGLKMAVQ  
 
       370        380        390        400        410        420  
PMDGQPPSTL DESVPDLGQI QTALAGIFVA ILGFETRELD FIDQLPLTEL GISSVNAVEL  
 
       430        440        450        460        470  











        10         20         30         40         50         60  
MKHHHHHHHH GGLVPRGSHG SQSMPDLISQ KTHETRVNMS DIGQVVADYY DQVTESLKQK  
 
        70         80         90        100        110        120  
IGSQEVYLLF APFQERVEGF SWLKMFFEPE KHREHFELTL QKQHELKSML YRLVEFANVH  
 
       130        140        150        160        170        180  
RIFDIGCGYA TDLIQLAKRH PQVRGWGFSI SLNQVEFGQQ RIQDEGLGER VQLSCNDSTK  
 
       190        200        210        220        230        240  
DPLPGLFDLI IGFEVVVHIA DKQGVFGNMA RHLSNNGTIV LADCVANTVT SINTSYIGQY  
 
       250        260        270        280        290        300  
TSTAEEYSDI LAQNGLAIVD CVDVGPEISN FLYDPNYLEN AAYLSSIYPE MVNIEKEHQG  
 
       310        320        330        340        350        360  
WSNFGKALEV NLVRYVLLTI RKATASQTYD HLLQINLERL GSGALSYAEA LQAYPHIEQI  
 
       370        380        390        400        410        420  
VIEQIAETKS PDSNATTTSV ADIEQTIVEL AAQVLEMMPD EVNTQARFID FGVDSLRGLI  
 
       430        440        450        460        470        480  













        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MRVETGAKVE VKEESPNVVS GYYNRFAAEV DPKEEIYLIF  
 
        70         80         90        100        110        120  
PFFPEKLPGF SWLMTFFEPH RRPEHARYML ARQKDMKAVL YRHVDFSRVR TVMDIGCGLA  
 
       130        140        150        160        170        180  
TDLIQLAQRH PKLSADGFTI AQKQVDVART RIARAGLSER LHIDCRDSSR DPFPRRYDLI  
 
       190        200        210        220        230        240  
IGFEVVFHIE DKNGVFSNIA EHLEEGGLVV LADGVANTVT EINLPHLGQF TSTVPQLAEI  
 
       250        260        270        280        290        300  
LGRHGLRVVS CVDTSEGVSR FLDDDRLEEN LARLRSEYPE SAHDEGQHRG WANFGKALGA  
 
       310        320        330        340        350        360  
RLIRYLLFTL EKAPAGEDRA GLVLLNQSRI EGAQPFPSAL QALEAKRLDP VRTASSADIS  
 
       370        380        390        400        410        420  
IERQLVAVAA EVFEMAPTEL DPTASFKDYG IGSLTGLRFI DAVNRRLHLR LKMEHFFQCP  
 
       430        440  










        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MDEEDETMSA PLQVAADHDA TDAFQRWLHA GIRAGVESLL  
 
        70         80         90        100        110        120  
KLSGERLRDT ANFADLGFDS IGLAHFGRWL SRRFGIDVTP DLFFDHSTIV ALVAHLSAAS  
 
       130        140  
















        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MPSAGARAAT VREALERVMI DTLGVSPAEL RAARSFAELG  
 
        70         80         90        100  
















        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MQPMDGQPPS TLDESVPDLG QIQTALAGIF VAILGFETRE  
 
        70         80         90        100        110        120  
LDFIDQLPLT ELGISSVNAV ELLEAINTEF DLHLPTSLVF ECHRLEDLAG HIQVELGRKP  
 
       130  
















        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MTSVADIEQT IVELAAQVLE MMPDEVNTQA RFIDFGVDSL  
 
        70         80         90        100        110  



















        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MASSADISIE RQLVAVAAEV FEMAPTELDP TASFKDYGIG  
 
        70         80         90        100        110  




Figure S14: Raw and deconvoluted ESI-MS spectra for RizM18ACP(II). 
 
MisM1OMT 
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MGSSHHHHHH SSGLVPRGSH MQSMPDLISQ KTHETRVNMS DIGQVVADYY DQVTESLKQK  
 
        70         80         90        100        110        120  
IGSQEVYLLF APFQERVEGF SWLKMFFEPE KHREHFELTL QKQHELKSML YRLVEFANVH  
 
       130        140        150        160        170        180  
RIFDIGCGYA TDLIQLAKRH PQVRGWGFSI SLNQVEFGQQ RIQDEGLGER VQLSCNDSTK  
 
       190        200        210        220        230        240  
DPLPGLFDLI IGFEVVVHIA DKQGVFGNMA RHLSNNGTIV LADCVANTVT SINTSYIGQY  
 
       250        260        270        280        290        300  
TSTAEEYSDI LAQNGLAIVD CVDVGPEISN FLYDPNYLEN AAYLSSIYPE MVNIEKEHQG  
 
       310        320        330        340        350        360  








Figure S15: Raw and deconvoluted ESI-MS spectra for MisM1OMT. 10 % 




 10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MMTPELDLES TDASALLADL RGGRRTAQDA VAASLARIER  
 
        70         80         90        100        110        120  
LNPRVNAIVT LDAERAMNEA RAADARLAAG QPAGLLHGLP ITVKDAIFTE GMRTTAGHAP  
 
       130        140        150        160        170        180  
LRDQVPERDA TAVARLRAAG AIVIGKTNCA TLCSDLQTNN PVFGRTSNPW DASRTAGGSS  
 
       190        200        210        220        230        240  
GGDAAAVALG LVPLGIGTDT GGSIRVPAAY CGVYGFKPSL AAVPGDGVIP PLASGEGHAD  
 
       250        260        270        280        290        300  
SLTTIGPIAR SVRDLRLAYR VLSGDALADA PAPAATRIAW TDPFAAVPVD DSVRAALARA  
 
       310        320        330        340        350        360  
RDLLSATGLQ VERREPPFDP RRVNYHYLLL SLYEFTPREL KPGVHFAFRL AETLRSLFGG  
 
       370        380        390        400        410        420  
GLAGSYAKVK AWQRTQIDAY QAFADGIDAW VIPATPTVAF PHQSGARALN LVSEGKRVQA  
 
       430        440        450        460        470        480  








        10         20         30         40         50         60  
MHHHHHHGKP IPNPLLGLDS TENLYFQGID PFTMTALLFP GQGAQEASMC EGVAAMPAFA  
 
        70         80         90        100        110        120  
SRYRFVCDAA GADILDAVAR HGERVLHRNL FSSLLTVLVA SLSLDAFRAR EAAAPEAVAG  
 
       130        140        150        160        170        180  
YSVGQWTALY AAGVVDFEQL VGLIVERARA MDACFEETAG GMSAVIGVRE EALERELASL  
 
       190        200        210        220        230        240  
RESGHAVFIS NINCVGQYSI AGTLDALDRA EQRISGLRPK KLVRLPVSGA WHCPLLAEAE  
 
       250        260        270        280        290        300  
QRFAAVLARV RLASPRLPVA DNVTGGWLPE APDALRATLA AHLTRPVRWR DCVRTLIAAG  
 
       310        320        330  















    
        10         20         30         40         50         60  
MKHHHHHHHH GGLVPRGSHG SHAGPRATVA FMFPGQGSQK RGMGAGLFDS VPEYAAVERE  
 
        70         80         90        100        110        120  
VDALLGYSMR ALCHEDPDGR LKETQYTQPA LYVVNALHYY DAIARGQRPD YVAGHSLGEY  
 
       130        140        150        160        170        180  
NALLAAGAFD LLTGLRLVKK RGELMAASVS GGMAAVIGMD EGRIKQVLTE NGLGTIDVAN  
 
       190        200        210        220        230        240  
FNSPSQIVIS GPVADIARGH TVFEDAGART YVILPVSAAF HSRYVEETGR AFADFIAPMR  
 
       250        260        270        280        290        300  
FEALRIPVIS NVSARPYEAK DPSATIKSLL VQQITRPVQW VQSVSFLMAQ GVKEFREIGP  
 


















        10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MQDKIQQFLS DRLLVDFDRD VDADSDLFQL GLMDSETYAE  
 
        70         80         90        100  
























       10         20         30         40         50         60  
MGSSHHHHHH SSGLVPRGSH MLPKAAVAPA SRAVVAASAK PVRDLAAELA RGLAQALCME  
 
        70         80         90        100        110        120  




















Figure S20: Sequence alignment of all embedded OMT domains from trans-
AT PKSs. Residues are shaded if there is greater than 60% sequence 
conservation and the darker the shade of purple the greater the extent of 
conservation. The star indicates the proposed  key catalytic base. This image 













Figure S21: Ramachandran plot created using RAMPAGE software to assess 







Appendix 4: MS data for assays looking at the substrate tolerance 






Figure S22: Stacked deconvoluted ESI-MS spectra of MisM9OMT-ACP with 
ACP bound simplified substrate mimics after incubation with SAM. The 
spectra where methylation (+14 Da) is observed are highlighted in purple. 
The peaks marked with an * are from the gluconoylated protein where the 












Figure S23: Stacked deconvoluted ESI-MS spectra of MisM1OMT-ACP with 
ACP bound simplified substrate mimics after incubation with SAM. The 

















Figure S24: Stacked deconvoluted ESI-MS spectra of RizM18OMT-ACP with 
ACP bound simplified substrate mimics after incubation with SAM. The 
spectra where methylation (+14 Da) is observed are highlighted in purple. 
The peaks marked with an * are from the gluconoylated protein where the 
















Figure S25: Base peak chromatograms from LC-MS analyses of purified 
amide gladiolin (purple), iso-amide gladiolin (blue) and gladiolin (black). For 
each chromatogram a blank is shown in grey to indicate peaks that are 






















Figure S26: High-resolution MS analysis of amide gladiolin in positive ion 
mode. 
 










Figure S28: 13C NMR spectrum of amide gladiolin recorded in DMSO-d6. 
 
 















































Table S1: NMR assignments for iso-amide gladiolin (DMSO-d6, 600 Hz). * 
indicates that the signal was found under the DMSO-d6 peak. Multiplicity is 
denoted as follows: s = singlet, d = doublet, dd = doublet of doublets, dt = 

















































dH (J, Hz) dC 
 1 - 170.41 
 2 2.15, 2.45, 2 x 1H, 2 x m 39.6* 
 3 3.72, 1H, m 68.35 
 4 1.45, 1H, m 43.5 
 4-Me 0.76, 3H, d, (6.9) 9.7 
 5 3.84, 1H, m 69.1 
 6 1.35, 1.48, 2H, m, ol 39.3* 
 7 3.55, 1H, m 71.7 
 8 1.51, 1H, m 37.7 
 8-Me 0.79, 3H, d, (6.7) 13.1 
 9 1.93, 2.16, 2 x 1H, 2 x m 36.5 
 10 5.73, 1H, dt, (6.8, 14.3) 133.6 
 11 6.31, 1H, dd, (11.0, 14.8) 126.57 
 12 6.01, 1H, ol 130.1 
 13 5.27, 1H, ol 125.2 
 14 2.28, 2.38, 2 x 1H, 2 x m 30.1 
 15 3.21, 1H, m 79.6 
 15-OMe 3.23, 3H, s 55.7 
 16 1.36, 1H, m 31.8 
 17 1.22, 1.36, 2 x 1H, 2 x m 20.6 
 18 1.24, 1.32, 2H, m, ol 38.2 
 19 3.64 66.8 
 20 1.35, 1.47, 2 x 1H, 2 x m 39.3 
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 21 3.82, 1H, m 66.3 
 22 1.80, 1H, m 42.2 
 22-Me 0.71 3H, d, (7.0) 10.6 
 23 5.24, 1H, m 72.2 
 24 5.00, 1H, d, (9.2) 123.1 
 25 - 139.1 
 25-Me 1.69, 3H, s 16.6 
 26 2.03, 2H, ol 39.06* 
 27 2.13, 2H, m 30.3 
 28 5.51, 1H, m 131.3 
 29 5.96, 1H, m, ol 130.7 
 30 5.96, 1H, ol 131.7 
 31 5.57, 1H, m 129.4 
 32 2.09, 2H, m 41.6 
 33 3.50, 1H, m 67.5 
 34 1.04, 1.28, 2 x 1H, 2 x m 43.9 
 35 1.60, 1H, m, ol 28.4 
 35-Me 0.80, 3H, d, (6.5) 18.9 
 36 2.02, 2H, m, ol 32.5 
 37 1.30, 1.46, 2 x 1H, 2 x m 32.9 
 38 - 174.5 









Table S2: MIC values determined for iso-amide gladiolin against C. albicans, 









Klebsiella pneumonia DSM26371 >64 
Acinetobacter baumannii DSM25645 16 
Pseudomonas aeruginosa DSM29239 >64 
Enterobacter cloacae DSM16690 >64 
Escherichia coli SY327 32 
Burkholderia gladioli BCC1622 >64 
Gram-positive bacteria 
 
Enterococcus faecium DSM25390 2 
Staphylococcus aureus DSM21979 8 
Mycobacterium  
Mycobacterium tuberculosis H37Rv 4 
Fungi 
 












Figure S37: Phylogenetic analysis of AT-like domains from trans-AT PKSs. Tip 
labels consist of the protein name and domain architecture (in the case of 
proteins with more than one AT domain the appropriate AT domain is shown 
and the other is denoted with X). Highlighted in purple are the hypothesised 
succinyl-specific AT domains and tip labels in blue indicate that the AT 
domain utilizes a non-malonyl substrate. Sequences from the following 
pathways were used: Gbn, gladiolin (Burkholderia gladioli); Etn, etnangien 
(Sorangium cellulosum So ce56); Kir, kirromycin (Streptomyces collinus); 
Ozm, oxazolomycin (Streptomyces albus); Sor, sorangicin (Sorangium 
cellulosum So ce12); Bat, batumin (Pseudomonas fluorescens); Bon, 
bongkrekic acid (Burkholderia gladioli); Bae, bacillaene (Bacillus 
amyloliquefaciens); Bas, basiliskamides (Bacillus laterosporus); Ped, pederin 
(Pseudomonas sp.); Tai, thailandamide (Burkholderia thailandensis); Ooc, 
oocydins (Serratia marcescens); Riz, rhizopodin (Myxococcus stipitatus); 
Mis, misakinolide (uncultivated symbiont of the marine sponge Theonella 
swinholides); Cal, calyculin (uncultivated symbiont of the marine sponge 
Discodermia calyx) and Psy, psymberin (uncultivated symbiont of the marine 
sponge Psammocinia aff. bulbosa). 
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Figure S38: (A) Plasmid map for the bacterial expression vector, pET24a. 
Restriction sites within the multiple cloning site (MCS) are shown. The location 
of the origin of replication (ori), repressor for the lac promoter (lacI), lac 
operator, transcriptional promotor and terminator from the T7 phage (T7 
promoter/terminator), replication regulator protein encoding gene (rop),  
ribosomal binding site (RBS), kanamycin resistance gene (KanR) and the 
optional C- terminal histidine tag coding sequence (6xHis) are indicated. Bp, 
base pairs. (B) Sequence of the designed N- terminal histidine tag included 


















Figure S39: Plasmid map for the bacterial expression vector, pET28a. 
Restriction sites within the MCS are shown. The location of the origin of 
replication (ori), repressor for the lac promoter (lacI), lac operator, 
transcriptional promotor and terminator from the T7 phage (T7 
promoter/terminator), replication regulator protein encoding gene (rop),  
ribosomal binding site (RBS), kanamycin resistance gene (KanR) and N- (and 




Figure S40: Linearized plasmid map for the bacterial expression vector, 
pET151. Blunt-end PCR products with a 5’ CACC overhang are cloned into 
the vector at the DNA break shown. The location of the origin of replication 
(ori), repressor for the lac promoter (lacI), lac operator, transcriptional 
promotor and terminator from the T7 phage (T7 promoter/terminator), 
replication regulator protein encoding gene (rop),  ribosomal binding site 
(RBS), ampicillin resistance gene (AmpR) and N- terminal histidine tag 





Figure S41: Linearized plasmid map for the bacterial expression vector, pET-
SUMO. PCR products with a 3’ A overhang (added by Taq polymerase) are 
cloned into the vector at the DNA break shown.  The location of the origin of 
replication (ori), repressor for the lac promoter (lacI), lac operator, 
transcriptional promotor and terminator from the T7 phage (T7 
promoter/terminator), replication regulator protein encoding gene (rop),  
ribosomal binding site (RBS), kanamycin resistance gene (KanR), SUMO 





Figure S42: Plasmid map for the bacterial expression vector, H-MBP-3C. 
Restriction sites within the MCS are shown. The location of the origin of 
replication (ori), repressor for the lac promoter (lacI), lac operator, 
translational tac promoter and rrnB terminator, replication regulator protein 
encoding gene (rop), ampicillin resistance gene (AmpR), MBP solubility tag 





Figure S43: Plasmid map for the mutagenesis vector, pGPI. Restriction sites 
within the MCS are shown. The location of the defective origin of replication 
(R6K γ ori), origin of transfer (oriT), transfer genes (traJ and traI), trimethoprim 




Figure S44: Plasmid map for the bacterial expression vector, pMLBAD. 
Restriction sites within the MCS are shown. The location of the origin of 
replication (pBBR1 oriV), arabinose inducible promoter (araBAD promoter),  
translational regulatory gene (araC) and rrnB terminator, replication regulator 
protein (pBBR1 Rep), gene for conjugal transfer of plasmid (mob) and 
trimethoprim resistance gene (TpR) are indicated. 
 
